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Abstract 
 Ractopamine is a repartitioning agent that can increase muscle growth and has led to our 
interest in determining the mechanisms involved in enhancing muscle growth.  Therefore, three 
studies were conducted to determine the impact of ractopamine on growth in cattle.  The first 
experiment evaluated the impact of increasing metabolizable protein supply to finishing heifers 
fed ractopamine.  Three different diets were fed to increase the amount of metabolizable protein 
reaching the small intestine, and the diets contained urea, solvent soybean meal, or expeller 
soybean meal as the primary supplemental protein source.  From this study it was determined 
that increasing metabolizable protein supply above that present in typical feedlot diets containing 
urea and steam-flaked corn is not necessary to improve responsiveness to ractopamine.  The 
second experiment evaluated the effect of feeding ractopamine to growing Holstein steers 
implanted with trenbolone acetate/estradiol.  Half of the steers were implanted 28 days prior to 
all steers receiving ractopamine for the final 28 days; this model represents an intense implant 
program.  The mode of action of the ractopamine and of steroidal implants was different based 
on their different effects on serum insulin-like growth factor (IGF)-I and longissimus expression 
of IGF-I mRNA.  Additionally, administering a combination of the two growth promotants, 
based on nitrogen retention, yields a less than additive response using our model of growing 
Holstein steers.  The third study was conducted to evaluate the differential response to 
ractopamine of implanted, finishing steers and heifers.  Treatments were steer vs. heifer and 0 vs. 
200 mg/d ractopamine fed for the final 28 days.  This study attempted to address some questions 
generated from the previous study, which were how serum and local tissue production of IGF-I 
are affected by ractopamine.  Ractopamine had different effects on serum IGF-I between steers 
and heifers and numerically increased IGF-I mRNA abundance in longissimus and biceps 
femoris muscles.  Additionally, ractopamine impacted protein turnover differently in different 
muscles and changed myosin heavy chain IIA expression.  The effect of ractopamine on IGF-I 
warrants more research.  These experiments aid in our understanding of the mode of action of 
ractopamine in cattle.               
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based on nitrogen retention, yields a less than additive response using our model of growing 
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200 mg/d ractopamine fed for the final 28 days.  This study attempted to address some questions 
generated from the previous study, which were how serum and local tissue production of IGF-I 
are affected by ractopamine.  Ractopamine had different effects on serum IGF-I between steers 
and heifers and numerically increased IGF-I mRNA abundance in longissimus and biceps 
femoris muscles.  Additionally, ractopamine impacted protein turnover differently in different 
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Introduction 
In today’s market, more pounds of lean meat are in demand from the livestock industry.  
Feeding livestock to produce more pounds of lean meat is the largest cost factor.  For that reason, 
decreasing the feed required per unit of gain or product produced would improve cost 
effectiveness.  In the last 40 years, production efficiency has been improved and accomplished 
by the use of growth promotants.  Anabolic steroids have been used extensively.  These 
compounds improve gain efficiency and rate of gain, thus making them cost effective.  In 
addition, compounds called phenethanolamines or adrenergic agonists have started be used for 
improving production efficiency.  However, there are different classes of adrenergic agonists and 
within each class, each compound possess a different potency due to the conformational 
structure.     
Chemical Properties of Phenethanolamines 
Phenethanolamines are similar in structure to the catecholamines, epinephrine and 
norepinephrine (Smith, 1998).  Phenethanolamines are comprised of β-adrenergic agonists (β-
agonist), β-antagonists, and α-adrenergic agonists, and some are categorized specifically within 
the β- and α-adrenergic agonist subfamilies.  All phenethanolamines share common features and 
must retain these features in order to have biological activity.  Phenethanolamines must contain a 
substituted six-membered aromatic ring bound to a β-carbon in the R configuration, a positively  
charged nitrogen in the ethylamine side chain, and a bulky R side chain on the aliphatic  
nitrogen (Weiner, 1980) as shown in Fig. 1.1.  However, differences in activity between  
phenethanolamines result from different substitutions on the aromatic ring as shown in Fig. 1.1 
(A, B, and C) and substitutions of the R group adjacent to the aliphatic nitrogen.  A list of 
different β-agonists is shown in Fig. 1.2.  Substitution on the aromatic ring can alter activity of 
the compound resulting in β-agonists that elicit differential responses.  For example, 
isoproterenol and dobutamine, which are categorized as catechols, have a hydroxyl group 
substitution at A and B in the Fig. 1.1.  These substitutions lead to rapid inactivation via 
methylation by catecholamine O-methyl transferase (COMT; Kopin, 1985).  Ractopamine and 
ritodrine, which are hydroxylated at the B position only, are not substrates for COMT, but are 
inactivated by enzymes in the intestine and liver (Smith, 1998).  In addition, substituting with 
halogen atoms instead of hydroxyl groups, such as in clenbuterol, renders the conjugative 
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biotransformation enzymes ineffective while allowing these compounds to retain full binding 
capacity to the receptors (Morgan, 1990).    
Lipophilic properties of β-agonists are important when looking at biological activity.  
Halogen substitutions on the aromatic ring such as on clenbuterol and cimaterol increase the 
lipophilicity of the compounds and allow them to interact with the cell membrane and, 
subsequently, the receptor (Witkamp, 1996).  In addition, the β-carbon of phenethanolamines is a 
chiral carbon, which indicates the presences of different stereoisomers with the levorotatory 
stereoisomer having greater activity compared to the dextrorotatory stereoisomer (Ruffolo, 
1991).  Such compounds include clenbuterol, ractopamine, isoproterenol, and 6-amino [[(1-
methyl-3-phenylpropyl) amino] methyl]-3-pyridine methanol dihydrochloride (L-644,969).  Thus, it 
is apparent that all phenethanolamines are similar in structure, but small modifications, which 
create different structures and different β-agonists, can result in differences in biological activity.         
β-adrenergic Receptors 
There are many cell types present in a mammalian body and almost all have β-adrenergic 
receptors (βAR) integrated into the plasma membrane (Mersmann, 1998).  The βAR contains 
approximately 400 amino acids and spans the plasma membrane 7 times.  This configuration 
results in 3 extracellular loops and 3 intracellular loops.  Ligand binding occurs in the center of 
the 7th transmembrane domain and interaction with the GS protein occurs in portions of the 2, 3, 
and 4 intracellular loops.  Three βAR have been identified thus far; β1, β2, and β3.  Within 
species, there is approximately 40 to 50% homology between receptor subtypes (Mersmann, 
1998).  Across species, any given βAR subtype has 75% or greater homology (Pietri-Rouxel and 
Strosberg, 1995).       
For β-agonists to elicit a response, they must bind to one of the βAR (Mersmann, 1998). 
Epinephrine and norepinephrine, as shown in Fig. 1.2, are known physiological β-agonists.  
Administration of synthetic β-agonists orally can lead to alteration in skeletal muscle and adipose 
tissue growth by repartitioning nutrients away from fat depots and toward muscle deposition.  
Beta-agonists bind to the βAR which results in an activated βAR/ GS complex.  The activated 
βAR complex catalyzes the exchange of GTP for GDP on the α subunit of the G protein.  The αS-
GTP directly activates adenylate cyclase, which catalyzes the conversion of adenosine 
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP).  Cyclic AMP binds to the 
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regulatory subunit of protein kinase A (PKA) in order to liberate the catalytic subunit that 
ultimately phosphorylates a number of intracellular proteins/enzymes (Mersmann, 1998).  
Phosphorylation by PKA can lead to activation of a number of proteins such as hormone 
sensitive lipase, which is the rate limiting step in lipolysis (Mersmann, 1998).  In contrast, 
phosphorylation by PKA can lead to inactivation of a number of proteins such as acetyl CoA 
carboxylase, which is the rate limiting step in lipogenesis (Liggett and Raymond, 1993).  In 
addition, PKA can impact gene expression by phosphorylating transcription factors such as the 
cAMP response element binding protein (CREB; Mersmann, 1998).  This transcription factor 
binds to the cAMP response element in the promoter region of certain genes to activate or 
inactivate gene transcription.  Subsequently, administration of β-agonists and activation of the 
βAR leads to changes in adipose tissue accretion such that lipogenesis is decreased and lipolysis 
is increased.  In addition, βAR activation leads to increases in muscle growth such that protein 
synthesis is increased and protein degradation is decreased (Mills and Mersmann, 1995).  The 
resulting increases in muscle growth will be discussed later in this review.   
The use of β-agonists in the livestock industry today is to improve growth in beef cattle, 
lambs, swine, broilers, and turkeys; however, β-agonists are not equally effective in all species 
(Anderson et al., 1991).  Overall, beef cattle and lambs show larger responses to 
phenethanolamines than swine, with the smallest response in chickens (Moody et al., 2000).  
Beef cattle and lambs show a greater response to the β2-agonists, clenbuterol, cimaterol, and L-
644,969, whereas swine show a lesser response (Moody et al., 2000).  Additionally, differential 
responses between tissues within species and different muscle types are observed.  Research 
conducted in finishing beef steers (Winterholler, 2006) and heifers (Sissom et al., 2007) 
demonstrated a greater abundance of mRNA for the β2-AR compared to the β1- and β3-AR in 
longissimus (LM).   In agreement, Sillence and Matthews (1994) reported that cattle 
predominately have β2 adrenergic receptors in skeletal muscle and adipocytes.   Similarly, Van 
Liefde et al. (1994) observed that adipose tissue in cattle contains approximately 75% β2- and 
25% β1-adrenergic receptors.   Similar results were observed in adipose tissue of lambs (Bowen 
et al., 1992).  Ractopamine is more effective in swine than in beef cattle and is even less 
effective in lambs (Moody et al., 2000).  In accordance, McNeel and Mersmann (1999) observed 
that the predominant β-adrenergic receptor transcript in the heart left ventricle, lungs, skeletal 
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muscle, and subcutaneous adipose tissue of pigs was that for the β1-adrenergic receptor as 
measured by quantitative ribonuclease protection assays. 
Receptor Desensitization 
As mentioned above, exposure of the βAR to β-agonist leads to increases in cAMP 
concentration and this response occurs within minutes of exposure (Hausdorff et al., 1990).  
With continued exposure to the β-agonist, concentrations of cAMP would be expected to 
increase; however, concentrations of cAMP following continual stimulation with β-agonists, 
plateau or even return to nadir concentrations (Johnson et al., 1978).  A decline in cAMP 
concentrations in response to continuous exposure to β-agonist is said to occur via 
desensitization.  Desensitization is functionally defined as an attenuation of hormonal 
responsiveness upon agonist stimulation (January et al., 1997).  
 Two separate processes can accomplish desensitization and are a result of acute or 
chronic exposure to a β-agonist. Acute βAR desensitization occurs with exposure in a short 
period of time and results in a rapid reduction in cAMP concentrations (Hausdorff et al., 1990).  
Removal of the desensitizing agent will attenuate desensitization within minutes.  Acute βAR 
desensitization occurs via decreased agonist nonspecific responsiveness, which is a result of 
phosphorylation of the βAR by PKA or by the cAMP independent kinase, β-adrenergic receptor 
kinase (βARK) or by both (Sibley et al., 1987).  Phosphorylation of the βAR decreases the 
capability of the ligand-receptor complex to activate the GTP/GDP exchange on the α subunit of 
the G protein (Sibley et al., 1987).  Chronic βAR desensitization can occur and the exact 
mechanism involved is still unknown, but Hausdorff et al. (1990) suggests that chronic exposure 
results in loss of the receptor via down-regulation or via internalization and receptor degradation 
or via both.  Sibley et al. (1987) reported that long-term exposure to a desensitizing agent 
activated βARK, which initiated internalization of the βAR.  Then phosphatases in the vesicle 
remove phosphates from the receptor and the receptor is not degraded.  When the desensitizing 
agent is removed, the receptors are recycled back to the plasma membrane to maintain basal 
levels.  In addition, Collins et al. (1989) demonstrated that long-term exposure of the β2-receptor 
in DDT1MF-2 hamster smooth muscle cells to a desensitizing agent led to an 80% decrease in β2-
receptor number and a 50% decrease in mRNA abundance.  Depression in mRNA abundance of 
the β2-receptor was a result of decreased stability and not a decline in transcription rate.  
  
 
Salmet
erol (β2) 
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 The Bmax (number of receptors) of β2-receptor in the plantaris muscle was reduced by 
37.7% and in the soleus muscle by 29.8% with no change in KD in rats when fed 10 ppm 
cimaterol for 14 d (Kim et al., 1992).  Similarly, Spurlock et al. (1994) reported β2-receptor 
density in the middle and outer layers of subcutaneous adipose tissue was reduced by 50% in 
pigs weighing 78 kg fed 20 mg ractopamine/kg of diet for 24 d compared to control pigs.  In the 
same study, ractopamine did not affect β2-receptor density in skeletal muscle indicating that 
desensitization induced by ractopamine differs between skeletal muscle and adipose tissue.  
Sainz et al. (1993) demonstrated similar results in β-receptor density in pigs fed 20 mg 
ractopamine/kg of diet for 3 wk prior to harvest.  In contrast, ractopamine fed for 28 d 
significantly increased β2-receptor mRNA expression in the semimembranosus (SM) of 
trenbolone acetate/estradiol 17β (TBA/E2)-implanted crossbred yearling steers (Winterholler et 
al., 2007) and tended to increase β2-receptor mRNA expression in the SM of implanted yearling 
heifers.  Winterholler et al. (2006) demonstrated a tendency for β1-receptor mRNA abundance to 
increase in LM of implanted yearling steers fed ractopamine for 28 d.  
Much of the aforementioned data demonstrates that exposure of animals to β-agonists for 
an extended period of time results in a loss of responsiveness to the β-agonist and down-
regulation of the receptor.  However, this response may differ between species and between 
muscle and non-muscle tissues. 
FDA Approved β-agonists 
The addition of β-agonists to diets of livestock animals is increasing due to the recent 
FDA approval of β-agonists.  Ractopamine-HCl, marketed as Optaflexx™, can be fed up to 400 
mg per head daily to feedlot cattle for the last 28 to 42 d of the finishing period.  Ractopamine-
HCl, marketed as Paylean™, can be fed up to 10 mg/kg of diet per head daily to pigs for the last 
20.4 to 40.8 kg of gain.   Zilpaterol-HCl, marketed as Zilmax™, can be fed from 60 to 90 mg per 
head daily to feedlot cattle for the last 20 to 40 d of the finishing period, but with a 3
 
d 
withdrawal period prior to harvest. 
  Growth and Carcass Performance and β-agonists 
The goal of the livestock industry is to increase meat production.  This includes the use of 
growth promotants such as steroidal implants and β-agonists.  As previously mentioned, β-
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agonists are repartitioning compounds that redirect nutrient supplies away from fat deposition 
and toward muscle growth.  Therefore, addition of β-agonists to the diets of meat producing 
animals can be beneficial.   
Research on the response of pigs to ractopamine has conclusively demonstrated benefits.  
Armstrong et al. (2004) reported 19 and 20% increases in average daily gain (ADG) and gain 
efficiency (G:F) with no effect on dry matter intake (DMI) in barrows fed 10 ppm ractopamine 
for the final 27 d.  Additionally, the authors observed a 5.2 kg gain in hot carcass weight (HCW), 
a 2% increase in dressing percentage (DP), a 14% increase in 10th-rib LM area, and an 8% 
increase in fat-free carcass lean with no change in 10th-rib fat depth and marbling score.  See et 
al. (2004) observed 8, 8, and 16% increases in ADG, DMI, and G:F in barrows and gilts fed 20 
ppm ractopamine from 71.2 to 109 kg body weight (BW; 41 d).  These results were observed in 
pigs fed ractopamine consistently over the feeding period and in pigs stepped up on ractopamine 
by feeding 5 ppm for weeks 1 and 2, 10 ppm for weeks 3 and 4, and 20 ppm for weeks 5 and 6.  
In the same study, HCW was increased by 2.7 and 2.0 kg in the constant and step up ractopamine 
treatment.  When HCW was used as a covariate, 10th-rib backfat depth, 10th-rib LM muscle 
area, and % fat-free lean were increased by 30, 12, and 6% by the constant ractopamine 
treatment and by 33, 15, and 8% by the ractopamine step up treatment.  In contrast to the study 
conducted by Armstrong et al. (2004), See et al. (2004) demonstrated a 27% decrease in 10th-rib 
backfat depth in the constant ractopamine treatment and a 20% decrease for the step up 
treatment.  The changes in the composition of gain with ractopamine supplementation, which 
were increases in muscle deposition and decreases in fat deposition, resulted in improved feed 
efficiency.  Bark et al. (1992) demonstrated a 10 and 15% increase in ADG and G:F with no 
effect on DMI in genetically lean barrows fed 20 ppm ractopamine from 63 to 104 kg BW with 
the greatest response observed in barrows with a high lean tissue growth rate.  Increases in 
muscle deposition in the ham, loin, shoulder, and belly in the low lean growth pigs were 12% 
and were 20% in the high lean growth pigs.  Additionally, fat deposition in the ham and shoulder 
decreased by 4% in the low lean growth pigs and by 3% in high lean growth pigs.  Changes in 
management practices, in addition to changes in genetics, have resulted in an abundance of 
leaner pigs when placed in the finishing period (Hollis and Curtis, 2001), and the current data 
suggest that genetically leaner pigs would benefit more from ractopamine feeding.  
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Data on the response of pigs to β2-agonists has not been as conclusive.  Cromwell et al. 
(1988) showed a 3 and 4% increase in ADG and G:F with no change in DMI in barrows and gilts 
fed 0.50 ppm cimaterol from 62 to 107 kg BW.  Dressing percentage and HCW were increased 
by 1 and 2%; however, 10th-rib backfat depth was decreased by 15% and 10th-rib LM area were 
increased by 12%, which resulted in a 5%  increase in percentage of carcass muscle.  Large 
responses in BW and carcass gains are not observed in pigs fed cimaterol; nonetheless, changes 
in composition during growth occur and consequently an improvement in the lean to fat ratio is 
observed.  Jones et al. (1985) demonstrated no change in ADG, a 7% decrease in DMI, and a 9% 
increase in G:F when barrows and gilts were fed 0.5 ppm cimaterol for 7 wk.  Jones et al also 
observed a 10% increase in muscle and a 10% reduction in fat, which explains the improvements 
in G:F.  Increases in muscle deposition were observed in the LM, biceps femoris (BF), and 
semitendinosus (ST), whereas the reduction in fat deposition was primarily observed at the 10th-
rib.  Compositional growth is altered in pigs fed cimaterol with slight improvements in BW and 
carcass gains, but large responses are observed in performance and carcass traits when pigs are 
supplemented with ractopamine.    
β-agonists are not used extensively in the poultry industry.  Feeding of β-agonists to 
poultry has resulted in a range of responses.  Dalrymple et al. (1984) demonstrated a 5% 
improvement in ADG and G:F with no effect on DMI in broiler chickens fed 1 ppm clenbuterol 
for 11 d.  Additionally, changes in body composition were observed with a 1.5% increase in 
muscle deposition and a 7.5% decrease in fat deposition.  Daily gains and G:F were improved by 
15 and 10% when turkeys were fed 22 ppm ractopamine for 2 wk (Wellenreiter and Tonkinson, 
1990).  Turkeys demonstrated a larger response to the ractopamine relative to the response 
observed in broiler chickens administered the β2-agonist, clenbuterol.   
The response of cattle to ractopamine feeding is less than the response observed when 
they are administered a β2-agonist.  Schroeder et al. (2005a) demonstrated 20 and 21% increases 
in ADG and G:F with no effect on DMI in feedlot steers fed 20 ppm ractopamine for the final 28 
to 42 d.  Schroeder et al. (2005b) reported 6.4 kg more HCW and a 3% increase in LM area, but 
no change in 12th-rib fat thickness, kidney, pelvic, and heart fat (KPH), yield grade, and quality 
grade in the same study.  Gruber et al. (2007) reported 15 and 17% improvements in ADG and 
G:F with no change in DMI in finishing steers initially implanted with 20 mg estradiol 
benzoate/200 mg progesterone and re-implanted 60 d later with 120 TBA/24 mg E2 when fed 
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200 mg ractopamine per head daily for the final 28 d.  Steers demonstrated a 5.5 kg gain in 
HCW, a 3% improvement in LM area, a greater percentage of carcasses with yield grade 2 (45.2 
vs. 30.8%), and a tendency to produce fewer carcasses with yield grade 3 (42.8 vs. 51.4%).  No 
changes were observed in DP, KPH, adjusted fat thickness, marbling score, and quality grade.  
Sachtleben et al. (2006a) observed 17 and 14% improvements in ADG and G:F with no change 
in DMI in feedlot steers implanted with 100 mg progesterone/10 mg estradiol benzoate 64 d 
prior to feeding 200 mg ractopamine per head daily for the final 34 d of the finishing period.  
With the same steers, Sachtleben et al. (2006b) demonstrated 5.8 kg more HCW in steers fed 
ractopamine compared to controls and observed no effect on DP, LM area, 12th-rib fat thickness, 
KPH, yield grade, and quality grade.  Winterholler et al. (2007) reported a 5 and 4% increase in 
ADG and G:F with no effect on DMI and 8 kg more HCW in yearling steers during the entire 
feeding period of 150, 171, or 192 d when initially implanted with 80 mg trenbolone acetate/16 
mg estradiol-17β and re-implanted with 120 mg TBA/24 mg E2 47, 68, or 89 d prior to feeding of 
200 mg ractopamine per head daily for the final 28 d.  Dressing percentage, LM area, 12th-rib fat 
thickness, KPH, yield grade, and marbling score were not affected.  However, larger responses 
are observed when ractopamine is fed at 300 ppm per head daily.  Avendaño-Reyes et al. (2006) 
reported 32 and 34% increases in ADG and G:F with a 2% decrease in DMI in finishing steers 
initially implanted with 100 mg progesterone/10 mg estradiol benzoate 105 d prior to study and 
re-implanted with 200 mg TBA/28 mg estradiol benzoate 60 d prior to feeding 300 mg 
ractopamine per head daily for the final 33 d.  Improvements in HCW and DP of 13.6 kg and 2% 
were observed in the same study, whereas no changes were reported in LM area and 12th-rib fat 
depth.  Similarly, Schroeder et al. (2005a,b) observed a 26% increase in ADG and G:F, 8.3 kg 
more HCW, 1 and 4% increases in DP and LM area, and no change in 12th-rib fat thickness, 
KPH, yield grade, or quality grade in steers administered 30 ppm ractopamine.  The 
aforementioned data in steers fed 200 mg/d ractopamine have demonstrated improvements in 
gains and efficiencies without affecting intake.  Additionally, carcasses were heavier, which is 
likely due to increases in muscle deposition as reflected by increases in LM area.  The 12th-rib 
fat depth was generally not affected, but there were changes in the yield grade distribution 
(Gruber et al., 2007).  Increases in the dosage of ractopamine to 300 mg per steer daily resulted 
in a greater increase in performance compared to 200 mg/d ractopamine. Relative to 200 mg/d, 
300 mg/d ractopamine tended to increase HCW, but other carcass traits did not change.       
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The response of finishing heifers to ractopamine has yielded results slightly different 
from that of steers.  Schroeder et al. (2005c) observed increases in ADG and G:F of 18 and 15% 
when heifers were fed 20 ppm ractopamine for the final 28 to 42 d and improvements of 21 and 
20% when heifers were fed 30 ppm ractopamine with no change in DMI.  Schroeder et al. 
(2005d) reported an increase in HCW of 2.9 kg with 20 ppm ractopamine and of 5 kg with 30 
ppm ractopamine fed to heifers with no changes in 12th-rib fat thickness, KPH, yield grade, or 
quality grade.  Longissimus muscle area did not improve in heifers fed 20 ppm ractopamine, but 
a 4% increase in LM area was observed in heifers fed 30 ppm.  Finishing heifers implanted with 
TBA/ E2 demonstrated 11 and 14% increases in ADG and G:F with a 3% decrease in DMI when 
fed 200 mg ractopamine per head daily (Laudert et al., 2007).  Additionally, HCW was increased 
by 4.6 kg and DP and LM area were increased by 1 and 2%, whereas 12th-rib fat thickness, 
KPH, yield grade, and marbling score were not affected by ractopamine feeding.  Quinn et al. 
(2006) reported a 33 and 34% increase in carcass gain and carcass efficiency with no change in 
DMI, marbling score, yield grade, or % USDA Choice in non-implanted heifers fed 200 mg/d 
ractopamine for 42 d or in those fed 100 mg/d for 14 d, followed by 200 mg/d for 14 d, and 300 
mg/d ractopamine for the final 14 d.  These data demonstrate greater response of heifers to 
ractopamine when fed for the final 42 d of the finishing period rather than feeding for 28 d.  
Sissom et al. (2007) demonstrated a 2 and 4% improvement in ADG and G:F with no effect on 
DMI over the entire feeding period in finishing heifers implanted initially with 200 mg 
trenbolone acetate or implanted initially with 80 mg TBA/8 mg E2 and re-implanted 60 d later 
with 200 mg TBA when fed 200 mg ractopamine per head daily for the final 28 d.  Hot carcass 
weight was increased by 5 kg, LM area was enhanced by 3%, 12th-rib fat depth was decreased 
by 7%, and calculated final yield grade was decreased from 2.61 to 2.44.  The decrease in 12th-
rib fat depth was a response not observed in other steer and heifer studies, but it is consistent 
with data from pigs fed ractopamine.  The heifer studies show lesser responses in growth and 
carcass performance than those with steers.  Similar to steers, heifers fed 30 ppm ractopamine 
demonstrated more improvement in growth performance, HCW, and LM area than heifers fed 20 
ppm ractopamine.  Additionally, these data suggest that growth and carcass performance in 
response to ractopamine in cattle are less than those observed in pigs.     
Finishing steers initially implanted with 100 mg progesterone/10 mg estradiol benzoate 
and re-implanted 60 d prior to the study with 200 mg TBA/28 mg estradiol benzoate 
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demonstrated 35 and 37% improvements in ADG and G:F with no change in DMI when fed 60 
mg zilpaterol per head daily for the final 33 d (Avendaño-Reyes et al., 2006).  In the same study, 
steers fed zilpaterol demonstrated increases in HCW of 21.9 kg, in DP of 3%, and in LM area of 
13% as well as an 18% decrease in 12th-rib fat depth.  Plascencia et al. (1999) observed no 
change in DMI and a 37 and 28% increase in ADG and G:F in feedlot steers fed 6 ppm zilpaterol 
for 42 d.  Hot carcass weight was increased by 13 kg, which was less than observed by 
Avendaño-Reyes et al. (2006).  Dressing percentage was increased by 3% with no changes in 
LM area, fat thickness, KPH, and marbling score.  Moloney et al. (1990) reported dramatic 
effects of the β-agonist, L-644,969, on performance and carcass characteristics of finishing steers.  
Dry matter intake was suppressed by 10% and ADG and G:F were increased by 53 and 69% in 
Friesian steers fed 1.0 ppm L-644,969 for 4 wk.  In addition, zilpaterol-fed steers had 23 kg more 
HCW, and DP and LM area were increased by 7 and 34%, whereas 10th-rib fat depth was 
decreased by 38.5%.  Wheeler and Koohmaraie (1992) demonstrated 77 and 86% increases in 
ADG and G:F in growing steers (initially weighing 350 kg) fed 3 ppm L-644,969 for 6 wk.  Carcass 
performance was altered as shown by improvements in HCW by 23.3 kg and in LM area by 24% 
and by a 21% decrease in adjusted fat thickness.  Clenbuterol administration to steers has also 
yielded dramatic results.  Schiavetta et al. (1990) reported 35 and 25% increases in ADG and 
G:F in young steers (initial wt = 250 kg) fed 7 mg clenbuterol daily for 50 d.  Furthermore, HCW 
was increased by 15 kg, LM area was increased by 28%, and yield grade was decreased from 2.6 
to 1.5.  In contrast, Ricks et al. (1984) demonstrated no effect of feeding 10 mg clenbuterol per 
head daily for 98 d to finishing Hereford steers on growth performance.  Hot carcass weight was 
not affected by treatment, but an 11% increase in LM area and 23, 37, and 38% decreases in 
KPH, 12th-rib backfat thickness, and USDA yield grade were observed due to treatment with 
clenbuterol.  The authors speculated that a high dose or a longer duration of feeding clenbuterol 
potentially could have limited growth responses because chronic exposure leads to receptor 
desensitization.  Nonetheless, clenbuterol did repartition nutrients to muscle tissue as shown by 
an increase in LM area and decreases in KPH, 12th-rib back fat, and yield grade.  Taken as a 
whole, these data show that feeding a β2-agonist to cattle yields more dramatic improvements in 
growth (rate of gain, efficiency, or carcass composition) than does feeding a β1-agonist.       
Responses to β-agonists in sheep are not of the same magnitude as observed in cattle.  
Kim et al. (1987) reported 29 and 14% improvements in total gain and feed efficiency in wether 
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lambs (initial BW = 34.5 kg) fed 10 ppm cimaterol for 8 wk.  Hot carcass weight in this study 
was increased from 24.3 to 29.5 kg when cimaterol was fed, which resulted in a 10% increase in 
DP.  Wether lambs initially weighing 27.8 kg demonstrated 6 and 8% increases in ADG and feed 
efficiency when fed 10 ppm cimaterol for 7 wk (Beermann et al., 1986).  Carcass traits 
demonstrated large changes due to cimaterol treatment as DP and LM area increased by 6 and 
26% and last rib backfat thickness and KPH decreased by 48 and 35%.  These data show the 
potent effects of cimaterol as a repartitioning agent as shown by changes in composition in 
wether lambs; this response was observed with minimal changes in ADG, DMI, and feed 
efficiency.   The effect of L-644,969 on performance of wether and ram lambs was less than that of 
cimaterol.  Koohmaraie et al. (1996) reported increases in ADG and LM area of 9 and 7% and a 
decrease in adjusted fat thickness of 6% in 17 wk old callipyge wether and rams lambs fed 4 ppm 
L-644,969 for 6 wk.  Due to the presence of the callipyge genotype, there may have been no 
potential for further improvements in growth, and this might explain the lesser response to the β -
agonist.       
β-agonists classified as β1 and β2 when fed to meat producing animals, specifically pigs, 
sheep, and cattle, enhance growth by repartitioning of nutrients.  Repartitioning occurs when 
adipose tissue becomes less sensitive to nutrient supplies in circulation and muscle tissue, on the 
other hand, becomes more sensitive.  Therefore, changes in composition of growth occur due to 
no change or an increase in lipolysis in adipose tissue and changes in the protein depositing 
machinery in muscle.  Protein turnover can be affected in various ways and will be discussed 
later in this review.  The magnitude of response to β-agonists depends on the β-agonist used and 
the species to which the β-agonist is administered.             
Skeletal Muscle Growth and β-agonists 
Administration of β-agonists to meat producing animals leads to large compositional 
changes in growth with lean muscle deposition increasing the most.  This process occurs via 
repartitioning of nutrients away from fat storage and toward skeletal muscle accretion.  Increases 
in lean muscle deposition are evident as shown by increases in individual muscle weights.  
Wether lambs initially weighing 17 kg demonstrated 33, 27, and 32% increases in the BF, SM, 
and ST when fed 10 ppm cimaterol for 7 wk (Beermann et al., 1987).  Wheeler and Koohmaraie 
(1992) observed a 22% increase in ST weight in steers initially weighing 346 kg fed 3 ppm of 
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L644,969 for 6 wk.  Bergen et al. (1989) observed a 25% increase in ST weight of barrows initially 
weighing 66.4 kg fed 20 ppm ractopamine for 28 d.  The BF, SM, and ST are muscles that are 
located in the round and have a greater distribution of fast twitch muscle fibers compared to 
other fiber types and, thus it appears that β-agonists impact them more.  Some data has 
demonstrated effects on muscle not located in the round.  Claeys et al. (1989) demonstrated a 
24% increase in ST weight of lambs fed 40 ppm of clenbuterol for 28 d whereas LM weight was 
not affected.  Similarly, Miller et al. (1988) demonstrated no change in LM weight in heifers 
initially weighing 393 kg at 12 months of age and fed 10 mg/d clenbuterol for 50 d.  In contrast, 
Jones et al. (1985) demonstrated 14, 9, and 15% increases in LM area, BF weight, and ST weight 
when barrows and gilts were fed 0.5 ppm cimaterol for 7 wk.  Bohorov et al. (1987) reported a 
29% increase in LM weight of wether lambs initially weighing 29.5 kg fed 10 ppm clenbuterol 
for 5 wk.  Bark et al. (1992) observed a 19% increase in LM weight in genetically low and high 
lean growth pigs fed 20 ppm ractopamine from 63 to 104 kg BW.   Additionally, an increase in 
primal cuts has been demonstrated with β-agonists.  Kim et al. (1987) reported 30, 24, 28, and 
26% increases in the leg, loin, rack, and shoulder primal cuts in wether lambs initially weighing 
34.5 kg fed 10 ppm cimaterol for 8 wk.  See et al. (2004) observed an 8% increase in boneless 
trimmed ham in barrows and gilts fed 20 ppm ractopamine from 71.2 to 109 kg BW (41 d).  
Boneless trimmed shoulder, belly, loin, and tenderloin were not affected by ractopamine 
treatment.  Although, poultry have been selected for high growth rate, responses to β-agonists 
feeding have been observed.  Rehfeldt et al. (1997) reported 20, 14, 16, and 8.5% increases in the 
extensor hallucis longus, gastrocnemius, BF, and pectoralis profundus muscles in male and 
female broiler chickens fed 1 ppm clenbuterol for 3 wk.  Gwartney et al. (1992) demonstrated 
24.1 and 23.5 g increases in the breast and leg muscles of broiler chickens fed 1 ppm cimaterol 
for 14 d.         
The aforementioned datum demonstrate dramatic increases in lean muscle mass and show 
that β-agonists impact muscle growth directly.  Skeletal muscle contains a heterogeneous 
population of muscle fibers that have the ability to differentially contract and metabolize energy.  
The contractile speed is dependent on ATPase activity of the myosin heavy chain (MHC); thus, 
there are 3 muscle fiber types in bovine skeletal muscle, type I, IIA, and IIX (Chikuni et al., 
2004).  Energy metabolism depends on the classification of enzymes used and, therefore, muscle 
fibers are classified as either oxidative, glycolytic, or both oxidative and glycolytic (Pette and 
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Staron, 1990).  Muscle fibers predominantly containing the MHC type I isoform are called slow 
twitch fibers due to their use during aerobic work, subsequently relying on oxidative metabolism 
to supply energy.  When the MHC type IIA and IIX isoforms are in greater abundance, the 
muscle fiber is called fast twitch fiber due to its use during anaerobic work which rely on both 
oxidative and glycolytic metabolism to supply energy.   
Demands from the livestock industry for lean red meat are increasing and because muscle 
fiber composition is related to animal performance in meat producing animals (Sosnicki, 1987), 
the use of certain stimuli are necessary to change muscle fiber composition.  Administration of β -
agonists has demonstrated changes in muscle fiber characteristics.   
Rehfeldt et al. (1997) reported a 12% increase in slow twitch fiber diameter in the 
extensor hallucis longus, an 8% increase in diameter of fast twitch type IIA fibers in the extensor 
hallucis longus muscle, and a 9% increase in diameter of fast twitch type IIA fibers in the 
gastrocnemius muscle in broiler chickens fed clenbuterol.  Response to clenbuterol resulted in 
changes of the percentage of fast twitch type IIA fibers from 41.5 to 36% and of fast twitch type 
IIB fibers from 38 to 44% in the extensor hallucis longus muscle.  Conversely, Aalhus et al. 
(1992) reported no change in percentage and diameter of red (type I slow twitch) muscle fibers in 
ST and psoas major of pigs (64 kg) fed 20 ppm ractopamine until slaughter BW of 100 kg was 
reached.  Fiber diameter of intermediate fibers (type IIA and IIX fast twitch) in ST and psoas 
major increased by 24% due to ractopamine; however, percentage of intermediate fibers 
decreased from 12.9 to 10.4%.  Fiber diameter of white fibers (type IIB fast twitch) in ST and 
psoas major increased by 17% and frequency increased from 72.8 to 77.3% due to ractopamine 
feeding.  The diameter of both intermediate and white muscle fibers increased; nevertheless, the 
distribution shifted to more white muscle fibers.  Oksbjerg et al. (1994) demonstrated no change 
in cross sectional area of slow twitch, fast twitch IIA, and fast twitch IIB in LM and BF of pigs 
initially weighing 25 kg and fed 3 ppm salbutamol until slaughter at 90 kg (avg. 92 d).  However, 
frequency of slow twitch fibers decreased from 12.3 to 10.7%, fast twitch IIA fibers decreased 
from 9.5 to 5.5%, and fast twitch IIB fibers increased from 78.2 to 83.8% in LM, whereas in the 
BF frequency of slow twitch fibers decreased from 23.6 to 19.5%, fast twitch IIA fibers 
decreased from 13.3 to 7.8%, and fast twitch IIB fibers increased from 63.2 to 72.7%.  These 
data support Aalhus et al. (1992) demonstrating the conversion of fast twitch IIA fibers to fast 
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twitch IIB fibers.  Additionally, the latter study demonstrates the ability of salbutamol to convert 
slow twitch fibers to fast twitch fibers.  
The data presented shows that administration of β-agonists either increases the size of 
each fiber type or converts slow fibers to fast glycolytic fibers.  Changes in the size of the fiber 
can be attributed to alterations in protein turnover that will be discussed later in this review.  A 
muscle is classified based on the fiber type distribution.  The fiber type profile in each muscle is 
determined by the neural input.  If the neural input is changed such as using cross-reinnervation, 
then the fiber type profile will change (Pette and Staron, 1997).  For instance, cross-reinnervation 
of a fast twitch muscle with a slow nerve converts the fast twitch muscle to a slow twitch muscle.  
Conversely, cross-reinnervation of a slow twitch muscle with a fast nerve converts the slow 
twitch muscle to a fast twitch muscle (Pette and Staron, 1997).  Additionally, changes in 
expression of MHC isoform can change the profile of a fiber and could provide an in vivo 
measure of changes in protein turnover.  Depreux et al. (2002) demonstrated 20, 33, and 32% 
decreases in MHC IIA mRNA expression on d 14, 28, and 42, and 42 and 48% decreases in 
MHC IIX mRNA expression on d 28 and 42, whereas MHC IIB mRNA expression increased by 
40 and 29% on d 28 and 42 with no change in MHC IA mRNA expression on d 14, 28, and 42 in 
ST and LM of pigs initially weighing 85 kg when 20 ppm ractopamine was fed.  Additionally, 
pigs fed 60 ppm ractopamine demonstrated 36 and 49% decreases in MHC IIA and 34 and 59% 
decreases in MHC IIAX mRNA expression on d 28 and 42, whereas MHC IIB mRNA 
expression increased by 35 and 60% on d 28 and 42.  Gunawan et al. (2007) reported no change 
in type I MHC gene expression, a gradual decrease of type IIA MHC gene expression to wk 1 
with an increase to control levels by 4 wk, a decrease in type IIX MHC gene expression 
throughout the feeding period, and an increase in type IIB MHC gene expression in pigs (initially 
weighing 90 kg) fed 20 ppm ractopamine for 4 wk.  In steers, Smith et al. (1989) demonstrated 
an increase in fast twitch myosin light chain (MLC) 1/3 mRNA expression in response to 0.72 
mg/kg BW ractopamine for 56 d.  These data indicate that changes in gene expression of MHC 
and MLC are induced by β-agonist feeding and could indicate either changes in fiber type profile 
or changes in protein accretion.    
Data reported on myofibril morphology in ruminants have demonstrated results similar to 
that in pigs.  Beermann et al. (1987) observed increases in type I fiber area in superficial ST, 
deep medial ST, and LM of 32, 29, and 13% and in type II fiber area in superficial ST, deep 
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medial ST, LM, SM of 29, 29, 15, and 55% in wether lambs fed 10 ppm cimaterol for 12 wk.  
The frequency of type I fibers decreased from 10.7 to 3.7% in medial ST, 3.6 to 0.4% in 
superficial ST, 3.5 to 0% in SM, and 0.7 to 0.2% in LM due to cimaterol feeding when compared 
to control lambs.  A decrease in the percentage of type I fibers resulted in an increase in the 
frequency of type II fibers in all muscles.  In contrast, Kim et al. (1987) observed no change in 
type I fiber area in LM and ST of wether lambs fed 10 ppm cimaterol for 8 wk.  Nonetheless, 
type II fiber area was increased by 50 and 51% in LM and ST of lambs fed cimaterol compared 
to controls.  Vestergaard et al. (1994) reported an increase in fiber area in type I fibers of 31% 
and in type IIB fibers of 69% in LM of Friesian bulls (initially weighing 162 to 407 kg) when fed 
0.06 ppm cimaterol for 90 d.  Frequency of type I fibers in LM decreased from 24.0 to 20.4% 
and type IIA fibers decreased from 24.2 to 8.6%, whereas frequency of type IIB increased from 
51.8 to 71.1%.  Additionally, in ST, type I and IIA fiber areas were not affected by cimaterol, but 
type IIB fiber area increased by 22%.  The percentage of IIA decreased from 24.3 to 6.7% and of 
IIB increased from 61.8 to 81.6% in the ST.  Wheeler and Koohmaraie (1992) demonstrated no 
change in fiber distribution of βR (β-red, slow twitch), αR (α-red, fast twitch IIA), and αW (α-
white, fast twitch IIb) in the LM when steers (initially weighing 350 kg) were fed 3 ppm L644,969 
for 6 wk.  However, βR fiber area decreased by 41% and αR and αW fiber area increased by 24.5 
and 7.6%.  Miller et al. (1988) demonstrate a 19% increase in type II fiber diameter with no 
change in type I diameter and frequency of type I and II in the LM of heifers fed 10 mg/d 
clenbuterol for 50 d.  Gonzales et al. (2007) observed no change in the percentage of type I and 
type II fibers in the LM of cull cows, initially weighing 370 to 418 kg, when fed 15 ppm 
ractopamine for 35 d.  In contrast, type I fiber area and diameter were increased by 31 and 15%, 
whereas type II fiber area and diameter were not affected by ractopamine.  In the latter study, 
MHC isoforms were detected by immunocytochemistry, but type IIX and IIB were not detected.  
Chikuni et al. (2004) did not detect type IIB mRNA from bovine muscle using real-time PCR, 
but did detect type IIX.  Pig skeletal muscle contains 4 types, I, IIA, IIX, and IIB.  
With the data at hand, β-agonists can alter muscle composition, alter expression profile of 
MHC, and increase of the diameter of each muscle fiber in pigs and cattle with little impact on 
poultry.  Myosin heavy chain expression changes such that type I, IIA, and IIX are down-
regulated and type IIB is up-regulated.  The distribution of muscle fibers is changed such that the 
fast, glycolytic and/or oxidative fibers increase, whereas slow, oxidative fibers decrease in 
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percentage.  In general, all muscle fiber types increase in size, but predominately the fast, type II 
fibers are impacted such that area and frequency increase. 
Improvements in muscle growth are observed when meat producing animals are fed β-
agonists.  As the previous section discussed, muscle composition is changed to favor the increase 
in lean muscle mass.  The increase in size or hypertrophy of the muscle fiber (cell) is due to 
changes in protein turnover: increases in protein synthesis, decreases in protein degradation, or 
both.  In addition, blood urea-N will decrease in animals fed β-agonists indicating improved 
utilization or decreased catabolism of amino acids.  Dunshea and King (1994) reported a 5% 
decrease in plasma urea-N in gilts fed 20 ppm ractopamine for 22 d.  Additionally, Eisemann and 
Bristol (1998) demonstrated a 19% decrease in plasma urea in 487 kg steers fed 80 ppm 
ractopamine for 15 d.  See et al. (2004) reported decreases in plasma urea-N of 27, 22, and 14% 
on d 7, 21, and 35 in pigs fed 11.7 ppm ractopamine.  These data demonstrate decreases in 
plasma urea-N with β-agonist feeding which results from increases in retained nitrogen in 
skeletal muscle.  Improvements in nitrogen retention are associated with increased uptake of 
amino acids into the muscle.  Data reported by Byrem et al. (1998) demonstrated 37, 66, 61, 52, 
47, 59, 55, 45, 45, and 46% increases in net flux of serine, tyrosine, arginine, histidine, lysine, 
phenylalanine, threonine, isoleucine, leucine, and valine into the hind limb of steers (initially 
weighing 250 kg) when arterially infused with 0.5 µg cimaterol/ min for 14 d.  Enhanced uptake 
of amino acids resulted from the direct action of cimaterol on muscle accretion.  
The use of isotopes can also give estimates of fractional protein turnover rates when 
animals are administered β-agonists and can further elucidate the direct impact β-agonists have 
on muscle growth.  Helferich et al. (1990) reported a 55% increase in fractional synthesis rate of 
α-actin, which constituents 23% of myofibrillar protein, in the LM of pigs when administered 20 
ppm of ractopamine for 21 d.  Additionally, α-actin mRNA expression and translational activity 
was enhanced 2-fold in pigs fed ractopamine.  Translational activity of other proteins was 
enhanced, and it can be concluded that ractopamine not only impacts gene expression, but also 
improves mRNA stability and production of the final protein product.  Similarly, Grant et al. 
(1993) reported 41 and 62% increases in α-actin mRNA expression in the LM muscle of pigs fed 
20 ppm ractopamine for 2 and 4 wk.  Using ELC5 (subclone of L6 myoblast) cell line, Anderson 
et al. (1990) demonstrated 12, 27, 18, 34, and 24% increases in [
35
S]-methionine incorporation 
into total protein of myotubes after 4, 24, 48, 72, and 96 h of incubation with 1 µM ractopamine. 
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Similarly, increases in [
35
S]-methionine incorporation were observed in 43-kDa proteins that 
represent either α-actin, creatine kinase, other sarcoplasmic proteins, or MHC proteins.  Bergen 
et al. (1989) reported that fractional protein synthesis and degradation rates were 4.4%/d and 
3.4%/d for control and 6.1%/d and 4.9%/d in the ST of pigs fed 20 ppm ractopamine for 21 to 35 
d.  Subsequently, fractional accretion rates were improved by 20% with ractopamine feeding and 
can be attributed to increases in both synthesis and degradation.  These data demonstrate that 
ractopamine-enhanced improvements in muscle growth are mediated, in part, by increases in 
protein synthesis.     
Claeys et al. (1989) demonstrated a 9.4%/d fractional synthesis rate in the brachialis 
muscle of lambs fed 40 ppm of clenbuterol for 28 d compared to only 6.1%/d for control lambs.  
Fractional degradation rates were not affected by clenbuterol treatment in that study.  Young et 
al. (1990) demonstrated a 10 to 12% increase in [
3
H]-leucine incorporation into myosin heavy 
chain and a 10 to 15% decrease in protein degradation rates in primary muscle cells prepared 
from broiler chicken leg incubated with 1 µM cimaterol for 7 d.  These data demonstrate the 
combined result of increases in protein synthesis and of decreases in protein degradation when 
primary muscle cells isolated from chickens are incubated with clenbuterol.  Wheeler and 
Koohmaraie (1992) demonstrated a 27.1% decrease in fractional protein degradation rates and a 
numerical increase in fractional protein synthesis rates after 3 wk in steers fed 3 ppm of L644,969.  
In contrast, Benson et al. (1991) demonstrated no change during 2 h incubations in [
14
C]-
phenylalanine incorporation into soleus muscle removed from rats fasted and treated with 2 ppm 
clenbuterol for 2 d.  No change in concentration of tyrosine in the media after 2 h incubation was 
observed.  However, concentration of 3-methylhistidine was significantly lower in the media at 0 
and 2 h of incubation of the treated muscle compared to control, indicating a reduction in protein 
degradation.  Release of tyrosine from the muscle reflects breakdown of total protein, whereas 
release of 3-methylhistidine reflects breakdown of myofibrillar proteins such as actin and 
myosin.  Therefore, clenbuterol treatment to fasted rats had no effect on protein synthesis, but 
decreased myofibrillar protein degradation.   Reeds et al. (1986) reported no change in muscle 
protein synthesis, but demonstrated decreases in protein degradation of 55, 39, 19, and 32% in 
the gastrocnemius and of 55, 25, 30, and 26% in the soleus muscle of rats on d 4, 11, 21, and 25 
when administered 0.2 ppm clenbuterol.   
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β-agonists greatly influence protein metabolism via suppression of protein degradation.  
Three major protein catabolic pathways are found in muscle: a lysosomal pathway (cathepsin B, 
D, and L, and their inhibitor, cystatin), a calcium-dependent pathway (µ-calpain, m-calpain, and 
their inhibitor, calpastatin), and an ATP-dependent ubiquitin-proteasome pathway.  The calcium-
dependent pathway or calpain system is key to skeletal muscle turnover.  The calpains are 
intracellular proteins found in the muscle fiber and are localized around the Z disk (Goll et al., 
2002).  The calpains initiate protein degradation in the muscle via cleavage of desmin, vinculin, 
talin, dystrophin, spectrin, titin, nebulin, troponin T and I, tropomyosin, and actinin which are 
proteins associated with the Z disk (Goll et al., 1998).  Actin and myosin constitute a majority of 
myofibrillar proteins and are not degraded by the calpain system.  Due to disassociation of the Z 
disk and release of other proteins, actin and myosin disassociate and are degraded by the 
lysosomal and/or proteasome system (Goll et al., 1998).  Calpastatin controls this process via 
down-regulation of µ-calpain and m-calpain which lead to decreases in protein degradation.  
Thus, administration of β-agonists could inhibit these proteolytic systems resulting in less protein 
being degraded.  Koohmaraie et al. (1991) demonstrated a 63% increase in calpastatin activity in 
the BF of lambs fed 4 ppm L644,969 for 6 weeks.  Activity of µ-calpain, m-calpain, cathepsin B or 
L, and cystatin were not affected by β-agonist treatment.  In addition, Parr et al. (1992) observed 
increases in activity of m-calpain and calpastatin by 27 and 76% in LM of steers fed 1.5 ppm 
cimaterol for 16 weeks.  In addition, mRNA levels of m-calpain and calpastatin were increased 
by 30 and 96% due to cimaterol treatment.  The authors were the first to report simultaneous up-
regulation of m-calpain and calpastatin due to β-agonist feeding and suggested that this may be 
the physiological response observed when β-agonist are used.  Forsberg et al. (1989) reported 58, 
57, and 52% decreases in activity of m-calpain, µ-calpain, and calpastatin in skeletal muscle (BF, 
gastrochemius, and SM) of rabbits fed 10 ppm cimaterol for 35 d.  Activity of cathepsin B and D 
were not affected by cimaterol treatment.  Reduced activity of calpastatin was not expected due 
to down-regulation of both calpains.  However, the authors mention that calpastatin activity that 
was present was enough to depress calpain activity.   
The ubiquitin-proteasome system is responsible for myofibrillar proteolysis after 
myofibrillar proteins have been cleaved from the sarcomere by the calpain system (Attaix et al., 
1998).  When proteins are degraded via the ubiquitin-proteasome system, they are first tagged by 
the 14-kDa E2 and E3-α protein, and the tagged proteins are then degraded by the 20S 
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proteasome (Yimlamai et al., 2005).  In a study conducted by Yimlamai et al. (2005), a hindlimb 
unweighting model was used to simulate muscle atrophy.  The authors demonstrated in mice 
subjected to hindlimb unweighting plus administration of 0.9 mg/d clenbuterol via drinking 
water for 14 d an attenuation of hindlimb unweighting induced atrophy and decreased ubiquitin 
conjugates only in the fast plantaris and tibialis anterior, but not in the soleus muscle compared 
to rats subjected to hindlimb unweighting.  These finding support the notion of β-agonist acting 
predominantly on protein catabolism and, in addition, these data show that clenbuterol only 
affected the proteolytic system in fast twitch muscles and not in slow twitch muscle.  
Based on the evidence above, β-agonists alter protein metabolism such that protein 
synthesis is increased, protein degradation is decreased, or both.  Ractopamine increases protein 
synthesis as shown by increased myofibrillar protein mRNA and protein production, whereas 
cimaterol and clenbuterol, β2-agonists, mostly decrease protein degradation via down-regulation 
of two proteolytic systems; however, some data on administration of β2-agonists have 
demonstrated increases in protein synthesis in addition to decreases in degradation.  
The aforementioned data demonstrate that β-agonist administration results in 
conformational changes in the muscle by changing muscle fiber type distribution.  Additionally, 
treatment with β-agonists leads to increases in protein accretion via inhibition of protein 
degradation, although some research demonstrated an additional increase in protein synthesis.  
Increases in protein accretion in response to β-agonists can be limited if the amount of DNA in 
each muscle fiber is not increased.  Muscle hypertrophy increases the area of cytosol associated 
with each nuclei (increasing the protein:DNA ratio), placing a greater demand on nuclei to 
initiate gene expression of myofibrillar and sarcoplasmic proteins.  Therefore, increasing DNA 
content in the muscle fiber could lessen the demand on the nuclei and would not limit the growth 
of the muscle fiber.  However, myofibril nuclei are mitotically inactive and therefore, muscle 
fibers require another source of DNA during postnatal muscle growth.  Satellite cells serve as the 
main source of DNA for muscle fibers during postnatal muscle growth (Moss and LeBlond, 
1971).  Satellite cells are mono-nucleated cells that lie in close proximity to a muscle fiber and 
are located between the basal lamina and sarcolemma (Mauro, 1961).  Satellite cells found in 
skeletal muscle were first discovered 45 years ago (Mauro, 1961).  In an unperturbed state, 
satellite cells are quiescent.  When activated by injury, stretch, exercise, or some signal, satellite 
cells undergo asymmetric division resulting in potentially half of the new daughter cells 
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undergoing differentiation and subsequently fusing with existing muscle fibers to aid in muscle 
regeneration or to sustain muscle hypertrophy (Hawke and Garry, 2001; Zammit and 
Beauchamp, 2001).  Therefore, these satellite cells serve as a reserve source of DNA that is 
needed for muscle repair or muscle growth. 
Grant et al. (1990) demonstrated a 200% increase in the number of nuclei in satellite cell 
culture (isolated from embryonic chick breast muscle) incubated with 1 µM ractopamine for 48 
h.  Ractopamine increased satellite cell activity, thus changing the DNA content in the cell.  
Grant et al. (1993) observed an 18% increase in DNA content with no change in DNA 
concentration in the LM of pigs fed 20 ppm ractopamine for 4 wk.  The increase in DNA content 
was enough to maintain the protein:DNA ratio.  Forsberg et al. (1989) reported 77, 55, and 54% 
increases in DNA content in BF, extensor digitorum longus, and gastrocnemius muscle of rabbits 
fed 10 ppm cimaterol for 35 d.  In contrast, Gonzales et al. (2007) demonstrated no change is 
fiber-associated nuclei and satellite cell number in satellite cells isolated from cull cows fed 
between 15 and 16.5 ppm ractopamine for 35 d prior to harvest.  Similarly, Beermann et al. 
(1987) showed no change in total DNA content with a subsequent decrease in DNA 
concentration in ST in lambs fed 10 ppm of cimaterol for 7 wk.   O’Connor et al. (1991) 
demonstrated 42 and 25% reductions in DNA concentrations in the ST of ram lambs fed 10 ppm 
cimaterol for 3 and 6 wk.  With 34 and 19% increases in ST weight at 3 and 6 wk of cimaterol 
feeding, protein:DNA ratio was increased by 76 and 51%.   Additionally, Rehfeldt et al. (1997) 
demonstrated no change in DNA content in the extensor hallucis longus muscle of male and 
female broiler chickens fed 1 ppm clenbuterol for 3 wk.  Gwartney et al. (1992) demonstrated 14 
and 18% decreases in DNA concentration of the breast and leg muscles of broiler chickens fed 1 
ppm cimaterol for 14 d.    
The current dogma on the response of skeletal muscle satellite cell proliferation to β-
agonist treatment is no change in activity or DNA content of the muscle fiber.  Any stimulus (β-
agonist) that increases cAMP concentrations in the cell is generally considered to inhibit cell 
proliferation (Dumont et al., 1989).  However, some of the data presented above demonstrated 
DNA accretion in skeletal muscle cells exposed to β-agonist treatment.  Dumont et al. (1989) 
reviewed the impact cAMP has on cell proliferation and concluded that other cell types can 
stimulate cell proliferation via cAMP.  It is possible that non-myogenic cell types found within 
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muscle (e.g., fibroblasts) respond to β-agonist administration by accreting DNA and make it 
appear that cell proliferation is enhanced in satellite cells.    
The previous data demonstrate clearly that β-agonists increase muscle growth.  Whether 
the actions of β-agonists are direct or indirect has not been extensively studied.  However, data 
reported by McElligott and Chaung (1988) and Young et al. (2002) demonstrate that the addition 
of serum from rats and chickens treated with clenbuterol to primary cell cultures resulted in no 
change in [
3
H]-thymidine incorporation, protein turnover rates, and cAMP production when 
compared to control cultures.  These data suggest that responses to β-agonists could be direct.  
Steroidal implants are utilized in the feedlot industry to improve muscle growth similar to β-
agonists.  Johnson et al. (1996a,b; 1998a,b) demonstrated that administering implants to feedlot 
cattle improves muscle growth that is mediated through increases in liver secretion and skeletal 
muscle production of insulin-like growth factor (IGF)-I.  The role of IGF-I in the response to 
steroidal implants will be discussed later in this review.  Insulin-like growth factor-I plays a 
pivotal role in postnatal muscle growth and myogenesis.   
Beermann et al. (1987) reported 46.5 and 21.5% decreases in serum IGF-I concentrations 
in lambs fed 10 ppm cimaterol for 6 and 12 wk compared to lambs not fed cimaterol.  
Additionally, Sainz et al. (1990) reported that soleus and extensor digitorum longus muscle 
samples collected from rats treated with 0.9 mg/d cimaterol for 11 d had less response to IGF-I in 
culture compared to control.  These data suggest that IGF-I may not play a role in β-agonist 
induced muscle growth.  In contrast, O’Connor observed no change in serum IGF-I 
concentrations in ram lambs initially weighing 34.5 kg and fed 10 ppm cimaterol for 3 or 6 wk.  
Dunshea and King (1994) noted a similar lack of change in IGF-I in pigs fed 20 ppm 
ractopamine for 22 d.  Plasma IGF-I concentrations were not affected by feeding of 1.5 ppm 
cimaterol to growing Friesian steers (12 wk old weighing 92 kg) for 16 wk (Dawson et al., 1993) 
or by feeding 0.4 ppm clenbuterol to ewe lambs initially weighing 20.4 kg for 80 d (Young et al., 
1995).  These data show differential circulating IGF-I responses to β-agonist treatment.  Grant et 
al. (1993) demonstrated no change in IGF-I mRNA expression in the liver and LM of pigs fed 20 
ppm ractopamine for 4 wk.  Yimlamai et al. (2005) using a hindlimb unweighting model to 
simulate muscle atrophy, demonstrated in mice subjected to hindlimb unweighting plus 
administration of clenbuterol for 14 d a decrease in IGF-I content in the fast plantaris but not in 
the tibialis anterior muscle compared to rats subjected to only hindlimb unweighting. In contrast, 
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Awede et al. (2002) demonstrated a 5-fold increase in IGF-I mRNA expression, a 8-fold increase 
in IGF binding protein (IGFBP)-4 mRNA expression, and a 5-fold increase in IGFBP-5 mRNA 
expression in the soleus muscle of 3 month old rats administered 10 ppm clenbuterol in the 
drinking water for 3 d.  Additionally, muscle IGF-I content transiently increased by d 1 to d 5, 
whereas serum concentrations of IGF-I decreased due to clenbuterol.  The early induction of 
muscle IGF-I content relative to increases in mRNA expression of IGF-I indicate clenbuterol 
initially impacts mRNA translational rate and/or posttranslational modifications in skeletal 
muscle.  The reason for decreases in circulating IGF-I is not known, but the action of clenbuterol 
seems to preferentially to be on skeletal muscle.  Additionally, the role of increased IGFBP-4 
when clenbuterol is administered is unclear, but increases in IGFBP-5 have been implicated in 
inhibition of cell proliferation via IGF-I independent action.  The IGFBP-5 is produced and 
secreted by porcine embryonic myogenic cells, translocated back into the cell and into the 
nucleus, and inhibits cell proliferation (Kamango-Sollo et al., 2005).  Potentially, clenbuterol 
could elevate local production of IGF-I resulting in muscle hypertrophy; however the elevation 
of IGFBP-5 mRNA could suppress satellite cell activation and proliferation limiting the action of 
IGF-I to changes in protein turnover.   
Administration of β-agonists has exhibited pronounced effects on muscle deposition.  
Slow to fast twitch fiber conversion or increases in slow and fast twitch fiber diameter is 
observed with β-agonists; however, in general, the fast glycolytic fibers are impacted the most 
when β-agonists are fed.  Changes in protein turnover are observed and, although some research 
demonstrated increases in protein synthesis, protein degradation is primarily affected by β-
agonist treatment.  The impact of β-agonists on skeletal muscle satellite cell proliferation and 
subsequently DNA accretion is still unclear, but, in part, β-agonists seem not to stimulate cell 
proliferation.  Additionally, it is unclear to what extent, if any, IGF-I mediates the effects of β-
agonists on muscle growth.   
Protein Level and Ractopamine in Pigs 
Lysine is typically the first limiting amino acid in swine diets, and supplementation of 
crystalline lysine has become a popular practice.  Baker et al. (1975) and Easter and Baker 
(1980) demonstrated that decreasing crude protein in the diet by 2%, which resulted in decreased 
pig performance, can be attenuated by the addition of 0.15% L-lysine-HCl.  Subsequently, more 
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crystalline amino acids are being added to replace a portion of soybean meal in the diet to insure 
adequate amino acids are available, to decrease cost, and to decrease fecal N excretion (Carter et 
al., 1996).   
With the increased demand for lean meat production, swine producers have begun to 
incorporate the β-agonist, ractopamine, into their diets.  Improving muscle growth with the 
addition of ractopamine could change the lysine requirement.  Apple et al. (2004) demonstrated 
linear increases in ADG, G:F, LM depth and area, fat free lean yield, and ham yield as 
lysine:metabolizable energy (lysine:ME) ratio increased from 1.7 to 3.1 g/Mcal and in pigs fed 
10 ppm ractopamine for 28 d.  Additionally, 10th-rib fat depth linearly decreased as lysine:ME 
increased.  Similarly, Webster et al. (2002) demonstrated linear increases in ADG, G:F, BW, 
HCW, lean percentage, and loin eye area as dietary lysine increased from 0.8 to 1.4% and as 
ractopamine increased in the diet from 0 to 10 ppm for 28 d.  Lysine requirements are increased 
to 1.4% when ractopamine is included in the diet and is greater than the lysine requirement of 1.1 
to 1.2% in pigs not fed ractopamine.      
Steroidal Implants  
The use of growth promoting compounds in meat producing animals has become a 
important strategy in the feedlot industry.  Anabolic steroids are growth promotants and have 
been utilized for nearly 45 yr (Johnson et al., 1996a).  Trenbolone is a synthetic androgen that is 
similar in structure to testosterone (Anderson, 1991).  Trenbolone acetate is 10 to 50 times more 
potent in eliciting responses than testosterone and, therefore, is used instead of testosterone 
(Bouffault and Willemart, 1983).  Hayden et al. (1992) demonstrated 3% increases in BW and 
7% increases in ADG in crossbred steers initially weighing 302 to 312 kg and implanted with 
300 mg TBA for 80 d.  In the same study, steers implanted with 24 mg E2 demonstrated 7 and 
20% increases in BW and ADG.  Additionally, implanting with 300 mg TBA plus 24 mg E2 
resulted in 11 and 37% improvements in BW and ADG.  Implantation with TBA plus E2 resulted 
in a synergistic response compared to the response in E2 implanted steers which was greater than 
steers implanted with TBA.  Bartle et al. (1992) reported 18 and 10% increases in ADG and G:F 
in finishing steers implanted with 140 mg TBA/28 mg E2 for 140 to 168 d compared to control 
steers and 10 and 7% increases in ADG and G:F when compared to steers implanted with 30 mg 
E2.  Daily gains and G:F in steers implanted with 140 mg TBA alone were not different from 
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control steers.  In the same study, steers implanted with 140 mg TBA/28 mg E2 demonstrated a 
5% increase in LM area and 7 and 5% decreases in KPH and marbling score compared to control 
and to TBA implanted steers.  Finishing steers implanted with 120 mg TBA/24 mg E2 
demonstrated 82, 34, and 25% increases in carcass protein gain over control steers at d 40, 115, 
and 143 of implantation (Johnson et al., 1996a).  These data suggest that the additional protein 
accretion occurs primarily in the first 40 d after implantation.  Taken together, the combined 
TBA/E2 implant yields greater responses in feedlot steers compared to TBA or E2 alone.   
Due to the anabolic effects of the combined use of TBA and E2 on protein accretion, the 
exact mechanism by which these effects are mediated had been studied and IGF-I has been 
observed to be involved (Hayden et al., 1992).  Johnson et al. (1996b) demonstrated 9, 13, and 
19% increases in circulating IGF-I concentrations in steers implanted with 120 TBA/24 mg E2 
for 21, 40, and 115 d.  The activity and half-life of IGF-I is under control of IGFBP and, 
therefore, was measured in serum samples.  Implanted steers demonstrated greater IGFBP-3 
concentrations on d 21 and 40 compared to non-implanted steers.  The increases in serum IGF-I 
and IGFBP-3 occurred at the same time when protein accretion was the greatest in implanted 
steers.  Additionally, serum was collected from implanted and non-implanted steers throughout 
the experiment and was used to determine its mitogenic activity.  Satellite cell proliferation was 
increased by the addition of serum from implanted steers when compared to the proliferation 
rates of cells cultured with serum from non-implanted steers.  Serum concentrations of IGF-I and 
to a greater extent IGFBP-3 increased due to implantation resulting in greater mitogenic activity.  
Johnson et al. (1998a) observed a 150% increase in hepatic IGF-I mRNA abundance in lambs 
implanted with 40 mg TBA/8 mg E2 for 40 d.  In the same study, finishing steers implanted with 
120 mg TBA/ 24 mg E2 for 40 d demonstrated a 68% increase in IGF-I mRNA expression in the 
LM.  Similarly, increases in IGF-I in the liver and SM (White et al., 2003) and in the LM 
(Pampusch et al., 2003; Dunn et al., 2003) have been demonstrated in steers implanted with the 
combination of TBA/E2.  Increases in hepatic IGF-I mRNA abundance coincide with elevated 
circulating IGF-I concentrations after implantation.  Localized production of IGF-I in muscle can 
initiate a response through an autocrine or paracrine action resulting in improved muscle 
accretion.  Additionally, IGF-I, being a potent mitogen, can stimulate proliferation and fusion of 
satellite cells into existing muscle fibers, increasing the DNA content of the cell.  Skeletal 
muscle satellite cells isolated from yearling steers implanted with TBA/E2 for 31 d had greater 
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[
3
H]-thymidine incorporation rates 24 and 34 h post plating, 43% more cells at 72 h post plating, 
and greater number of myotube nuclei than satellite cells isolated from steers not implanted 
(Johnson et al., 1998b). 
Collectively, these data show that implantation with both TBA and E2 yield synergistic 
responses compared to implantation with TBA or E2.  The combined use of TBA/ E2 yields 
improvements in protein accretion while simultaneously increasing serum IGF-I and IGFBP-3 
concentrations, IGF-I mRNA expression in the liver, SM, and LM, and stimulating skeletal 
muscle satellite cell proliferation in vitro.  
 
Factors Affecting Response to β-agonists 
Differences between genders in growth performance are apparent and, therefore, 
differences between gender in response to β-agonists may be expected.  Rehfeldt et al. (1997) 
demonstrated improvements in ADG and feed efficiency of 8 and 7% in male broiler chickens 
and of 5 and 4% in female broiler chickens fed 1 ppm clenbuterol for 3 wk.  Male chickens 
demonstrated 11 and 4% increases in protein and fat gain, whereas female chickens showed a 
16% increase in protein gain and a 3% decrease in fat gain.  It is apparent that differences in 
response to ractopamine exist between genders.  Males demonstrated larger improvements in 
ADG, G:F, and carcass muscle gain, whereas females showed small ADG and G:F responses, 
but a larger change in carcass composition.  In swine, barrows grow faster than gilts; however, 
gilts are more efficient in lean tissue deposition that barrows (Friend and MacIntyre, 1970).  
Therefore, the addition of β-agonists to the diet might benefit barrows to a greater extent than 
gilts.  See et al. (2004) observed a 10% increase in ADG, a 2% increase in DMI, and a 10% 
increase G:F in barrows fed ractopamine, whereas gilts demonstrated a 2% increase in ADG, a 
13% decrease in DMI, and a 19% increase in G:F in gilts fed ractopamine compared to control.  
Additionally, gilts demonstrated 3 and 6% improvements in fat-free lean and boneless trimmed 
loin compared to barrows.  The data reported by See et al. (2004) suggest that, in pigs, the 
response to ractopamine in the gilts, being phenotypically leaner, was an improvement in lean 
muscle growth, whereas the response of barrows to ractopamine was an increase in BW with an 
improvement in gain efficiency.    
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In cattle, the response to administration of ractopamine in steers has demonstrated 
consistent results with an average of 5 to 6 kg of HCW added due to ractopamine feeding 
(Gruber et al., 2007; Sachtleben et al., 2006b; Schroeder et al., 2005b).  Response of heifers to 
ractopamine feeding has demonstrated on average an additional 0 to 5 kg of HCW due to 
ractopamine feeding (Laudert et al., 2007; Quinn et al., 2006; Schroeder et al., 2005d).  These 
results are inconsistent due to a lack of response such as that reported by Quinn et al. (2006).    
 
Conclusions    
In the context of this review, β-agonists are growth promotants that are used extensively 
to improve growth.  With the FDA approval of two β-agonists, ractopamine and zilpaterol, 
utilization of these compounds in the United States may increase in the years to come.  The 
addition of β-agonists to the diets of meat producing animals leads to improvements in daily 
gains and gain efficiencies as well as to increased kilograms of lean carcass produced, with the 
response being dependent on species, gender, and the β-agonist used.  The process is 
accomplished due to the repartitioning effects of β-agonists on nutrient supplies.  Furthermore, 
muscle fiber composition and/or diameter are altered in a way that permits skeletal muscle 
hypertrophy.  Skeletal muscle hypertrophy results from changes in protein turnover rates.  In 
general, β-agonists inhibit protein degradation, whereas protein synthesis is seldom affected.  β-
agonists appear not to affect DNA accretion; subsequently skeletal muscle satellite cell 
proliferation and differentiation are not affected.  It is unclear whether IGF-I mediates any of the 
actions of β-agonists, and this warrants further investigation.    
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Figure 1.1 Phenethanolamine backbone structure 
     Adapted from Smith (1998) 
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Figure 1.2 Names, structures, and classification of some phenethanolamines. 
   Adapted from Moody et al. (2000), Mersmann et al. (1998), and Smith (1998) 
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Abstract 
An experiment was conducted to determine the relationship between feeding ractopamine 
and different amounts of MP on growth and carcass characteristics of feedlot heifers.  Seventy-
two crossbred heifers (475 kg initial BW) were fed individually a diet based on steam-flaked 
corn for ad libitum intake for 29 d.  Heifers were implanted with 140 mg trenbolone acetate and 
14 mg estradiol-17β 60 d before the experiment. Treatments were arranged as a 2 × 3 factorial 
and included 0 or 200 mg ractopamine-HCl (23 ppm)/d, and either urea, solvent soybean meal 
(SSBM), or expeller soybean meal (ESBM) as the predominant protein supplement.  The 
amounts of MP supplied by the urea, SSBM, and ESBM diets were 688, 761, and 808 g/d, 
respectively, calculated according to Level 1 of the NRC (2000) model.  Body weights were 
obtained 1 d before ractopamine feeding and at slaughter.  Blood samples were obtained 1 d 
before starting the experiment and 13 d later.  Ractopamine improved ADG, gain efficiency, 
carcass-adjusted ADG, and carcass-adjusted gain efficiency (P < 0.01).  For ADG, heifers 
demonstrated a ractopamine × protein source interaction (P < 0.05); heifers not fed ractopamine 
had greater ADG when fed ESBM than when fed urea, whereas for heifers fed ractopamine there 
were no differences (P ≥ 0.10) among protein supplements.  This interaction was not observed 
for carcass-adjusted ADG (P = 0.60).  Final live weights (P = 0.02) and carcass weights (P = 
0.01) were greater with ractopamine feeding.  Carcass marbling scores and yield grades were not 
affected by ractopamine or protein source (P ≥ 0.39).  Plasma total α-amino nitrogen and glucose 
concentrations decreased more from pretreatment concentrations when heifers were fed 
ractopamine (P < 0.05).  Feeding ractopamine to heifers for 28 d before slaughter improved daily 
ADG and efficiency of gain without any large effects on carcass characteristics.  The MP supply 
does not need to be increased from that provided by finishing diets based on steam-flaked corn 
with urea as the primary N supplement to allow maximal response to ractopamine by finishing 
heifers. 
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Introduction 
Diets for feedlot cattle typically contain 12 to 14% CP, with a majority of the protein as 
degradable intake protein (DIP; Galyean, 1996).  Milton et al. (1997) showed that addition of 
undegradable intake protein (UIP) to a diet based on dry-rolled corn, which increased CP from 
10.6 to 12.6%, did not improve performance of finishing steers and that DIP derived from corn 
and urea was sufficient to maximize performance.  Furthermore, increasing CP in a diet based on 
steam-flaked corn from 13% to 14.5% had no effect on feedlot performance, and urea was more 
effective in improving efficiency than was cottonseed meal (Gleghorn et al., 2004).  Taken from 
these data, feedlot diets containing urea as the predominant protein supplement supply adequate 
amounts of DIP and are sufficient to optimize gain and efficiency of feedlot cattle. 
Requirements for MP differ depending on rate and composition of gain.  Thus, MP 
requirements could be increased by growth promotants that cause cattle to grow faster and 
deposit more lean tissue.  Ractopamine is a β1 adrenergic agonist recently introduced for use in 
cattle in the United States.  Feeding β agonists (clenbuterol, cimaterol, zilpaterol) to cattle leads 
to marked alterations in metabolism that increase leanness and muscle accretion, with only 
moderate effects on fat deposition (Mersmann, 1998), which could increase MP requirements.  
Alternately, β agonists could enhance the efficiency with which cattle use MP, thereby leading to 
no change or even a decrease in MP requirements.  Feeding ractopamine to pigs increased lean 
tissue deposition, but pigs fed ractopamine required no change in dietary protein to achieve 
optimal response to ractopamine (Mitchell et al., 1991; Xiao et al., 1999).  Our objectives were 
to determine the impact of feeding ractopamine to heifers for 28 d before slaughter, and to 
determine whether the response of heifers to ractopamine is influenced by supplemental protein 
sources supplying differing amounts of MP. 
Materials and Methods 
Procedures for this study were approved by the Kansas State University Institiutional 
Animal Care and Use Committee.   
Mixed breed, medium- to large-framed heifers that were predominantly continental 
crosses (n = 72; 475 kg initial BW, range 393 to 583 kg) were used in a randomized complete 
block design with a 2 × 3 factorial arrangement of treatments to evaluate the effects of 
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ractopamine, and supplemental protein source (supplying differing amounts of MP) on growth 
and carcass characteristics.  Dietary treatments (Table 2.1) consisted of finishing diets based on 
steam-flaked corn, formulated to contain 13.7% CP, with urea, solvent soybean meal (SSBM), or 
expeller soybean meal (ESBM) as the primary supplemental protein source and with 0 or 200 
mg/d ractopamine-HCl (23 ppm; provided as Optaflexx; Elanco Animal Health, Indianapolis, 
IN).  Heifers were implanted with 140 mg trenbolone acetate and 14 mg estradiol-17β (Revalor 
H; Intervet, Millsboro, DE) 60 d before the experiment started.  All heifers had been fed and 
housed individually for 49 d prior to initiation of our trial, and all were fed a common diet based 
on steam-flaked corn for ad libitum consumption for 27 d prior to initiation of our trial.  Dietary 
treatments, which had little impact on heifer performance, had been applied between 27 and 49 d 
before initiation of our trial, and these prior treatments were randomly distributed among our 
treatments.  Heifers were allotted to one of 12 blocks based on frame size (score of 1 to 3, each 
representing roughly one-third of the heifers as the largest, middle, and smallest frame sizes), 
body condition (2 groups, with 1 containing the thinnest one-third of the heifers and the other 
containing the remainder), and BW, and were housed in individual pens (1.5 × 6 m).  Heifers 
were fed individually and were given ad libitum access to their diet for 28 d, which represents 
both the shortest feeding time for which ractopamine usage is labeled as well as the most typical 
feeding period for ractopamine by the feedlot industry.  Heifers were fed once daily at 0900 with 
bunk management designed to yield slick bunks at feeding.  Initial BW were measured 1 d 
before initiation of ractopamine feeding at 0800, and final BW were obtained at 0500 directly 
before heifers were shipped to a commercial abattoir. 
Hot carcasses were weighed at slaughter.  Percentage of KPH, 12th-rib fat thickness, 
marbling score, LM area, USDA yield grade (calculated), and marbling score of the carcasses 
were measured after a 24-h chill.  Marbling scores were determined by a USDA grader.   
Jugular blood samples were collected 1 d before initiation of ractopamine feeding at 0800 
and 13 d later at 0800.  Blood was collected into vacuum tubes (Becton Dickinson, Franklin 
Lakes, NJ) containing sodium heparin, immediately placed on ice, and centrifuged for 20 min at 
1,000 × g to obtain plasma.  Plasma samples were stored (–20°C) for later analysis of plasma 
urea (Marsh et al., 1965), total α-amino nitrogen (Palmer and Peters, 1969), glucose, and lactate 
(glucose/lactate auto-analyzer; YSI 2300 STAT Plus; YSI Inc., Yellow Springs, OH).   
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Data were analyzed by using the MIXED procedure of SAS System for Windows 
Release 8.1 (SAS Inst. Inc., Cary, NC).  The model included the effects of protein source, 
ractopamine, and ractopamine × protein.  Block was included as a random effect.  For final BW 
and HCW, initial BW was included as a covariate.  Treatment means were computed with the 
LSMEANS option.  When an F-test for protein or for the ractopamine × protein interaction was 
significant (P < 0.05), individual treatment means were separated with pairwise t-tests among all 
means.  
Diets were evaluated with Level 1 of the NRC (2000) model and with the Cornell Net 
Carbohydrate and Protein System 5.0 (CNCPS; Fox et al., 1992; Russell et al., 1992; Sniffen et 
al., 1992).  Inputs included DM intakes of 8.7 kg/d and BW of 480 kg (averages for our 
experiment).  For the NRC (1996-) evaluation, ESBM was assumed to contain 48% CP, with 
45% of CP being DIP; SSBM was assumed to contain 55% CP, with 65% of CP being DIP.  For 
both models, concentrated separator byproduct was considered similar to beet molasses with 
20% ash and 17.6% CP, with 100% of CP being DIP.  Nutrient contents of other feedstuffs were 
as specified by the models’ databases. 
Results and Discussion 
Performance data for heifers are presented in Table 2.2.  Dry matter intake was not 
affected by ractopamine or protein source (P ≥ 0.13).  Average daily gain was increased 18% by 
ractopamine (P = 0.02).  When daily gains were calculated from carcass weights, ractopamine 
increased ADG by 25% (P = 0.008).  Basing daily gains on carcass weights removes potential 
differences in gut fill, perhaps allowing a more accurate evaluation of heifer growth.  Similarly, 
Carroll et al. (1990) demonstrated an 11% increase in ADG in response to feeding 20 ppm 
ractopamine for 38 to 45 d in feedlot steers.  Preston et al. (1990) reported a 25% increase in 
ADG when feeding 20 ppm ractopamine to finishing steers for 46 d. 
Ractopamine increased (P = 0.002) gain efficiency by 17%.  Gain efficiencies calculated 
on the basis of carcass-adjusted BW were increased (P = 0.003) 26% by feeding ractopamine.  
Anderson et al. (1989), Carroll et al. (1990), and Preston et al. (1990) showed similar 
improvements in gain efficiencies due to ractopamine.  Schroeder et al. (2003a) and Laudert et 
al. (2004) demonstrated a 16% improvement in feed efficiency when feedlot steers were fed 20 
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ppm ractopamine for 28 or 42 d.  In a similar study, Schroeder et al. (2003b) reported a 14% 
improvement in feed efficiencies for feedlot heifers.   
Carcass-adjusted daily gain, gain efficiency, and carcass-adjusted gain efficiency were 
not affected (P ≥ 0.52) by protein source.  For ADG, heifers demonstrated a ractopamine × 
protein source interaction (P = 0.04).  Heifers not fed ractopamine had greater ADG when fed 
ESBM than when fed urea, whereas heifers fed ractopamine showed no response (P ≥ 0.10) to 
protein supplementation.  The response of heifers not receiving ractopamine suggests that 
performance was improved by increasing MP supply.  However, heifers receiving ractopamine 
showed numerical decreases in daily gains as MP was increased.  For heifers fed ractopamine, 
carcass-adjusted gains were numerically greater when they were fed the urea-supplemented diets, 
suggesting that there was no benefit to increasing the MP supply.  Feedlot steers implanted with 
trenbolone acetate and estradiol-17β had gain efficiencies that were numerically greater when the 
diet was supplemented with a combination of 75% feather meal: 25% soybean meal rather than 
50:50 or 25:75 of feather meal and soybean meal (Cecava and Hancock, 1994).  This suggested 
that aggressively implanted finishing steers might respond to increases in MP supply, but this 
response was not observed in our implanted heifers fed ractopamine.  Anderson et al. (1989) 
observed no interaction between dietary ractopamine-HCl (0 to 80 ppm) and dietary protein 
concentration (11 or 14% CP) for performance of finishing steers over a 56-d period, suggesting 
that, similar to our results, ractopamine feeding did not markedly increase the MP requirement. 
Protein source did not alter HCW (P = 0.65), but HCW was increased (P = 0.008) 6.9 kg 
when heifers were fed ractopamine.  Schroeder et al. (2003b) observed a significant increase in 
HCW from heifers fed ractopamine, with an improvement of 2.9 kg.  Schroeder et al. (2003a), 
Laudert et al. (2004), and Carroll et al. (1990) showed similar increases in HCW of feedlot steers 
fed 20 ppm ractopamine (6.4, 5.6, and 4.9 kg). 
Final BW were 8.3 kg greater when heifers were fed ractopamine (P < 0.02).  Heifers 
also demonstrated a ractopamine × protein source interaction (P = 0.04) for final BW that was 
similar to that observed for ADG.  Heifers not fed ractopamine had greater final BW when fed 
ESBM than when fed urea, whereas heifers fed ractopamine showed no response (P ≥ 0.10) to 
protein supplementation.  Data reported from previous studies showed a 7.2-kg (Schroeder et al., 
2003a) and 6.7-kg (Laudert et al., 2004) increase in final BW of feedlot steers and a 6.6-kg 
  47 
(Schroeder et al., 2003b) increase in feedlot heifers in response to 20 ppm ractopamine fed for 28 
or 42 d. 
Carcass data for heifers are shown in Table 2.2.  Dressing percentage, LM area, 12th-rib 
fat thickness, USDA yield grade, and marbling score were not affected by ractopamine or protein 
source (P ≥ 0.07).  This is in agreement with Schroeder et al. (2003b), who showed no response 
to ractopamine in feedlot heifers for dressing percentage, 12th-rib fat thickness, LM area, 
marbling score, USDA yield grade, or USDA quality grade.  The KPH of control heifers was 
least when SSBM was fed, whereas the KPH of heifers fed ractopamine was least when ESBM 
was fed (ractopamine × protein source interaction, P = 0.002).  These differences are unlikely to 
be of biological importance.  In our experiment, modest responses to the treatments for carcass 
characteristics would not be detected due to the number of heifers studied.   Previous research 
showed no effect of ractopamine on KPH in feedlot steers (Schroeder et al., 2003a; Laudert et 
al., 2004) or feedlot heifers (Schroeder et al., 2003b).  Schroeder et al. (2003a) and Carroll et al. 
(1990) reported that ractopamine fed to feedlot steers significantly increased dressing percentage 
and LM area.  These same responses in dressing percentage and LM area were also observed in 
feedlot heifers (Laudert et al., 2004).  With ractopamine feeding, lean muscle deposition 
increases, potentially leading to increases in LM area (Mersmann, 1998).   
Plasma metabolites are presented in Table 2.3.  Because differences among treatments 
existed before the experiment, changes in plasma metabolite concentrations after implementation 
of treatments were calculated and considered most appropriate for assessing treatment responses.   
The decrease in plasma glucose concentrations from before the experiment to d 13 was greater 
when heifers were fed ractopamine (P < 0.05).  Changes from pretreatment concentrations of 
plasma lactate were not different (P ≥ 0.14) among treatments.    
Treatment effects on changes from pretreatment concentrations were not observed for 
plasma urea (Table 2.3).  Shifting dietary N from DIP to UIP might be expected to decrease 
plasma urea concentrations as less ammonia is absorbed across the gut.  Urea production, 
however, is related to N intake above anabolic requirements, and our diets were isonitrogenous 
and yielded no effect on heifer growth.  The effects of ractopamine on plasma urea, if any, may 
have been difficult to detect because the increase in N deposition in response to ractopamine was 
only about 5% of N intake (the 0.29 kg/d increase in ADG would correspond to increases in 
deposition of N of about 9 g/d).  Total α-amino N could be expected to increase with increases in 
  48 
MP supply, but differences among diets were not observed.  Decreases from pretreatment 
concentrations for plasma total α-amino N were greater for heifers fed ractopamine (P = 0.004), 
suggesting that more AA were taken up by tissues in response to this growth promotant.  
Our diets were formulated to provide different amounts of MP to the heifers, with the 
urea diet providing the least and the ESBM diet providing the most.  Metabolizable protein 
balances for the urea, SSBM, and ESBM diets were calculated with models from Level 1 of the 
NRC (1996) and the CNCPS, and the results are shown in Table 2.4.  Both models predicted 
energy allowable gains that were less than those observed.  This is likely due to our heifers being 
individually fed in small pens, thereby minimizing activity of the heifers and reducing their 
nonproductive energy usage.  Because gains for the heifers were under predicted, MP 
requirements would also be under predicted, and MP balance would be over predicted.  
Prediction of MP balance by the NRC model showed that the urea diet was slightly deficient, but 
MP balances were positive with SSBM and more so with ESBM.  Predictions from the CNCPS 
showed all diets to be in a positive MP balance.  Lesser MP supply from the urea diet than from 
the SSBM and ESBM diets was also predicted.  The more positive MP balances predicted by the 
CNCPS than by the NRC can be attributed to 1) the lesser gain predicted by CNCPS, which 
results in lesser MP requirements, and 2) greater predictions of MP supply by the CNCPS, which 
resulted from greater predictions of microbial protein supply.  Both the NRC and CNCPS 
predicted the greatest ruminal N balance for the urea diet and the least for the ESBM diet, 
although the NRC predicted a 121 g/d difference among diets and the CNCPS predicted only a 
19 g/d difference.  Because ruminal N balance was predicted by the CNCPS to be negative for 
the ESBM diet, MP balance predicted by the CNCPS did not differ much between the SSBM 
diet and the ESBM diet.  In contrast, the NRC model, which predicted positive ruminal N 
balances for all diets, predicted a greater difference between the SSBM and ESBM diets.  
Predictions for MP requirements are based on heifers fed no ractopamine; MP requirements for 
heifers fed ractopamine would be greater if the efficiency of MP use for tissue gain is not 
impacted by the ractopamine. 
When not fed ractopamine, finishing steers generally do not respond to increases in MP 
supply above that provided by typical finishing diets containing little UIP supplementation 
(Gleghorn et al., 2004; Milton et al., 1997).  McCoy et al. (1998) demonstrated that steer calves 
fed a diet based on dry-rolled corn or dry-rolled corn and wet corn gluten feed for 168 d showed 
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no improvements in performance when supplemented with UIP (80% feather meal and 20% 
blood meal).  Barajas and Zinn (1998) observed minimal improvements in performance of 
heifers fed diets based on dry-rolled or steam-flaked corn when they were supplemented with 
cottonseed meal (10% of diet DM) during a 110-d finishing trial.  Although research evaluating 
the effect of MP supply on performance in finishing heifers is limited, MP requirements of 
heifers are predicted to be less than those of steers due to the lesser amount of protein deposited 
(NRC, 2000).          
It was unknown whether heifers fed ractopamine might respond to increases in MP 
supply because ractopamine increases growth rate and lean tissue deposition, which in turn might 
lead to a greater need for MP.  Our study demonstrates that heifers fed ractopamine did not 
respond to increased MP supply.  Thus, provision of adequate DIP to the diet by the addition of 
urea seems sufficient to meet the MP needs of ractopamine-fed heifers consuming typical 
finishing diets based on steam-flaked corn.  
Our results show that ractopamine fed for 28 d before slaughter to heifers implanted with 
trenbolone acetate/estradiol can improve daily gains and feed efficiency with little impact on 
carcass characteristics.  Our data do not support the concept that dietary metabolizable protein 
supply needs to be increased above that present in feedlot diets based on steam-flaked corn with 
urea as the primary nitrogen supplement to maximize the response of finishing heifers to 
ractopamine.  
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Table 2.1 Composition of the diets fed to finishing heifers 
 
Item Urea 
Solvent 
soybean meal 
Expeller 
soybean meal 
Ingredient -------------- % of DM -------------- 
Steam-flaked corn 82.4 77.0 75.7 
Concentrated separator byproduct 6.0 6.0 6.0 
Alfalfa hay 6.0 6.0 6.0 
Urea 1.5 0.5 0.5 
Solvent soybean meal – 6.6 – 
Expeller soybean meal – – 7.9 
Limestone 1.5 1.4 1.4 
Salt 0.3 0.3 0.3 
Vitamin/mineral premix 
1
 0.1 0.1 0.1 
Drug premix 
2
  2.2 2.2 2.2 
Nutrient, calculated    
CP 13.7 13.7 13.7 
Degradable intake protein,
3
 % of CP 69.3 62.7 57.3 
NEm,
3
 Mcal/kg 1.45 1.46 1.46 
NEg,
3
 Mcal/kg 2.36 2.37 2.37 
Ca 0.70 0.70 0.70 
P 0.26 0.29 0.29 
K 1.05 1.18 1.18 
1 
Provided (per kg diet DM) 60 mg Mn, 60 mg Zn, 10 mg Cu, 0.6 mg I, 0.25 mg Se, 0.1 mg 
Co, and 2,650 IU vitamin A.  
2 
Fed to provide (mg/heifer daily):  ractopamine-HCl (0 or 200 depending on treatment), 
melengestrol acetate (0.5), monensin (300), and tylosin (90).   
3
 Based on NRC (1996). 
  
5
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Table 2.2 Effect of ractopamine and dietary protein source on growth and carcass characteristics of finishing heifers 
 
No ractopamine  Ractopamine, 200 mg/d 
 
Item Urea 
Soybean 
Meal 
Expeller 
soybean 
meal  Urea 
Solvent 
soybean 
meal 
Expeller 
Soybean 
meal SEM 
Performance         
Initial BW, kg 475.9 474.9 475.4  475.6 475.4 475.6 6.5 
Final BW, 
1,2
 kg 515.1
a
 519.8
ab
 527.8
bc
  535.2
c
 527.6
bc
 524.9
abc
 4.5 
DMI, kg/d 8.55 8.53 9.01  9.14 8.89 8.29 0.35 
ADG, 
1,2
 kg 1.37
a
 1.53
ab
 1.81
bc
  2.06
c
 1.80
bc
 1.71
abc
 0.16 
G:F 
1
 0.157 0.178 0.198  0.222 0.201 0.206 0.013 
Carcass adjusted performance 
3
         
ADG, 
1
 kg 1.59 1.49 1.66  2.14 1.91 1.87 0.18 
G:F
a1
 0.185 0.175 0.184  0.234 0.225 0.225 0.020 
Carcass performance         
Hot carcass wt, 
1
 kg 318.0 316.4 319.3  327.8 323.7 322.9 3.2 
Dressing percentage 
4
 61.7 60.9 60.5  61.4 61.5 61.5 0.53 
KPH, 
2
 % 2.15
c
 1.96
ab
 2.17
c
  2.13
bc
 2.17
c
 1.92
a
 0.06 
LM area, cm
2
 91.5 83.5 81.6  86.1 90.4 91.3 3.5 
12th-rib fat, cm 0.69 0.66 0.76  0.74 0.85 0.76 0.09 
USDA Yield grade 1.73 2.05 2.31  2.13 2.00 1.81 0.20 
Marbling score 
5
 338 390 346  344 338 348 22 
 
a-c 
Within a row, means without a common superscript letter differ, P < 0.05. 
1 
Effect of ractopamine, P < 0.05. 
2 
Ractopamine × protein interaction, P < 0.05. 
3 
Computed by using final BW = hot carcass wt/0.61.
 
4 
Dressing percentage = (HCW/BW) × 100.
 
 
5 
Slight = 300 – 399. 
  
5
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Table 2.3 Effect of ractopamine and dietary protein source on plasma metabolites in finishing heifers 
 
No ractopamine  Ractopamine, 200 mg/d  
Plasma, mM Urea 
Solvent 
soybean 
meal 
Expeller 
soybean 
meal  Urea 
Solvent 
soybean 
meal 
Expeller 
soybean 
meal 
S
SEM 
Urea         
Pre-treatment 4.57 5.41 5.49  4.80 4.81 5.13 0.34 
Post-treatment 
1,2,3
 4.07 5.19 5.06  4.22 4.30 4.50 0.27 
Difference -0.50 -0.22 -0.43  -0.58 -0.51 -0.63 0.28 
Total α-amino nitrogen         
Pre-treatment 2.98 2.97 3.11  3.21 3.02 3.10 0.11 
Post-treatment 
1,2,4
 2.85
abc
 3.05
bc
 3.14
c
  2.95
abc
 2.82
ab
 2.71
a
 0.11 
Difference 
2
 -0.13 0.08 0.03  -0.27 -0.20 -0.39 0.12 
Glucose         
Pre-treatment 
2,4
 6.81
b
 5.20
a
 5.08
a
  5.89
ab
 6.71
b
 7.01
b
 0.49 
Post-treatment 
1
 6.56 5.48 5.02  5.24 5.90 5.95 0.37 
Difference 
2
 -0.25 0.28 -0.06  -0.65 -0.81 -1.06 0.44 
Lactate         
Pre-treatment 5.63 4.38 3.83  5.07 6.13 6.74 0.94 
Post-treatment 
1
 4.69 5.04 3.44  4.02 4.58 5.58 0.79 
Difference -0.94 0.66 -0.39  -1.05 -1.56 -1.16 0.88 
a-c 
Within a row, means without a common superscript letter differ, P < 0.05. 
1 
Blood samples collected 13 d after initiation of ractopamine feeding. 
2 
Effect of ractopamine, P < 0.05.  
3 
Effect of protein, expeller soybean meal = solvent soybean meal > urea, P < 0.05 
4 
Ractopamine 
 
× protein interaction, P < 0.05 
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Table 2.4  Metabolizable protein balances of heifers fed diets with different protein supplements 
Item Urea 
Solvent 
soybean meal 
Expeller 
soybean meal 
Prediction from NRC (1996), Level 1 
Energy allowable gain, kg/d 1.36 1.37 1.37 
MP required, g/d 697 698 698 
MP from diet, g/d 688 761 808 
MP from bacteria, g/d 404 406 404 
MP from UIP, g/d 
1
 284 355 404 
MP balance, g/d -8 63 109 
Ruminal N balance, g/d 169 109 48 
Prediction from Cornell Net Carbohydrate and Protein System 5.0
2
 
Energy allowable gain, kg/d 1.22 1.23 1.20 
MP required, g/d 623 629 631 
MP from diet, g/d 877 913 918 
MP from bacteria, g/d 625 618 564 
MP from UIP, g/d 
1
 253 295 354 
MP balance, g/d 254 284 287 
Ruminal N balance, g/d 4 0 -15 
Ruminal peptide balance, g/d -53 -22 -33 
 
1 
UIP = undegradable intake protein. 
2
 Cornell University, Ithaca, NY. 
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Summary 
Six Holstein steers (231 ± 17 kg) housed in metabolism crates were used in a randomized 
complete block design with three blocks of two steers based on previous serum insulin-like 
growth factor (IGF)-I concentrations.  One of the two steers in each block was implanted with 
120 mg trenbolone acetate and 24 mg estradiol-17β on day 0.  None of the steers were fed 
ractopamine-HCl the initial 28 days, and then all steers were fed 200 mg of ractopamine-HCl per 
steer daily from day 28 until the end of the trial.  Steers were fed a corn-based diet (62% rolled 
corn, 20% expeller soya bean meal and 15% alfalfa hay) twice daily with an average dry matter 
intake of 4.8 kg/day.  Blood and M. longissimus biopsy samples were collected prior to 
implantation and on days 14, 28, 42 and 56.  There was an implant × ractopamine interaction for 
retained nitrogen (p < 0.05); ractopamine feeding led to only small improvements in nitrogen 
retention for implanted steers (45.9 vs. 44.5 g/day), whereas ractopamine led to larger increases 
in nitrogen retention for non-implanted steers (39.0 vs. 30.4 g/day).  Implantation increased (p < 
0.05) and ractopamine tended to decrease (p = 0.06) serum IGF-I concentrations.  Implantation 
tended to increase (p = 0.16) and ractopamine decreased (p < 0.05) mRNA expression of IGF-I 
in the M. longissimus.  Ractopamine decreased mRNA expression of β1- and β2-receptors in M. 
longissimus (p ≤ 0.02).  The steroidal implant and the feeding of ractopamine both increased 
nitrogen retention in steers, but the combination did not yield an additive response.  The two 
growth promotants had opposite effects on serum concentrations of IGF-I and mRNA expression 
of IGF-I in M. longissimus. 
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Introduction 
Steroidal implants that contain trenbolone acetate (TBA)/estradiol-17β (E2) improved 
average daily gain and gain efficiency (Johnson et al., 1996a), increased serum insulin-like 
growth factor (IGF)-I (Johnson et al., 1996b; Dunn et al., 2003; Pampusch et al., 2003) and 
increased IGF-I mRNA expression in the liver of wethers and M. longissimus of steers (Johnson 
et al., 1998a; Dunn et al., 2003; White et al., 2003).  Additionally, satellite cells prepared from 
M. semimembranosus of steers implanted with TBA/E2 have a shorter lag phase when cultured 
compared with satellite cells collected from non-implanted steers, indicating a greater number of 
proliferating satellite cells in muscle of implanted steers (Johnson et al., 1998b).  Satellite cells 
that withdraw from the cell cycle fuse with existing myofibres, supporting myofibre hypertrophy.  
These data suggest that TBA/E2 improves muscle growth by its effects on circulating and local 
tissue concentrations of IGF-I and, subsequently, on satellite cell proliferation.  
Ractopamine is predominantly a β1-adrenergic agonist that has binding affinity for both 
β1- and β2-adrenergic receptors (Colbert et al., 1991).  Binding of ractopamine to the β-
adrenergic receptors elicits a response that results in increased lean muscle mass with little or no 
effect on adipose tissue deposition (Liu et al., 1994; Mersmann, 1998).  Ractopamine can 
improve daily gains and gain efficiencies by 17% and 18% in steers (Laudert et al., 2004) and by 
18% and 16 to 18% in heifers (Schroeder et al., 2003; Walker et al., 2006).  Unlike steroidal 
implants, cimaterol (a β2-agonist) did not affect DNA content in the M. semitendinosus in rams, 
although it increased the total RNA concentration of M. semitendinosus by 109% (O’Connor et 
al. 1991). Therefore, it appears that cimaterol had no impact on satellite cell proliferation, and 
the mechanism by which cimaterol induces skeletal muscle hypertrophy may be different from 
that of steroidal implants. 
With potential differences in mode of action between steroidal implants and β-agonists, 
additive or synergistic responses might be expected.  Our objective was to determine the effect of 
a TBA/E2 implant and of feeding ractopamine on several growth-related criteria in steers.  
 
Materials and Methods 
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Procedures for this study were approved by the Kansas State University Institutional 
Animal Care and Use Committee.   
Animals and experimental design 
Six Holstein steers (initially weighing 231 ± 17 kg and 6 months of age) castrated at 30 
days of age were used to evaluate the interaction between steroidal implantation and feeding 
ractopamine.  Steers were housed in individual metabolism crates in a temperature-controlled 
room (21°C) with continuous lighting.  Prior to the study, steers were adapted to the diet (Table 
3.1) for 1 week.  All steers had free access to water and were limit-fed the same diet (4.3 to 5.4 
kg/day of dry matter) in equal proportions at 12-h intervals; steers in each block were fed the 
same amount of feed.   
The experiment was arranged as a randomized complete block design with three blocks 
of two steers based on previous serum IGF-I concentrations with one steer in each block 
implanted with 120 mg TBA and 24 mg E2 (Revalor S
®
; Intervet, Millsboro, DE, USA) on day 0 
and the others not implanted.  None of the steers were fed ractopamine-HCl the initial 28 days, 
and then all steers were fed 200 mg per steer daily of ractopamine-HCl (Optaflexx
®
; Elanco 
Animal Health, Greenfield, IN, USA) beginning on the evening of day 28 and continuing 
through the end of the trial on days 56, 57, or 58. 
Nitrogen retention and diet digestibility 
Representative samples of the diet were collected daily, composited over 4-day periods 
and stored ( 20 °C).  Orts, if any, were collected, composited by steer over 4-day periods and 
stored ( 20 °C).  Faeces and urine for each steer were collected daily and weighed to determine 
the total output.  Urine was collected in buckets containing 300 ml of 6 M HCl to prevent 
ammonia loss.  Representative samples of faeces (5%) and urine (1%) were saved, composited 
by steer over 4-day periods, and stored ( 20 °C).  Collections were initiated 4 days before 
implantation to provide pretreatment values.  The first collection of urine and feces after 
ractopamine feeding was initiated on day 29.  Samples of the diet, orts and faeces were analyzed 
for dry matter (105 °C in forced-air oven for 24 h) and nitrogen using a Leco FP 2000 nitrogen 
analyzer (Leco Corp., St. Joseph, MI, USA).  Urine was analyzed for ammonia and urea 
concentrations colorimetrically (Technicon Industrial Systems, Buffalo Grove, IL, USA; Method 
No. 337-74T and 339-01, respectively).  
Blood metabolites and hormones 
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Jugular blood samples were collected 2 h after the morning feeding on days 0 (before 
implantation), 14, 28 (before ractopamine was fed), 42 and 56.  Blood was collected into vacuum 
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) containing sodium heparin, immediately 
placed on ice and centrifuged for 20 min at 1 000 × g to obtain plasma.  Blood was also collected 
into vacuum tubes without additives, allowed to clot for 24 h at 4 °C and then centrifuged for 20 
min at 1 000 × g to obtain serum.  Plasma samples were stored ( 20 °C) for later analysis of 
glucose (Gochman and Schmitz, 1972) and urea (Marsh et al., 1965).  Sera were stored ( 20 °C) 
for later analysis of insulin (radioimmunoassay kit, DSL-1600; Diagnostic Systems Laboratories, 
Webster, TX, USA; intra-assay CV = 5.3%, assay sensitivity = 0.02 ng/ml; Greenwood et al., 
2001) and IGF-I (IGF-I coated-tube immunoradiometric assay kit, DSL-5600; Diagnostic 
Systems Laboratories; intra-assay CV = 3.4%, assay sensitivity = 5.0 ng/ml; Greenwood et al., 
2001).  
Biopsy samples from M. longissimus 
Biopsy samples were collected from the M. longissimus from each steer as described by 
Dunn et al. (2003) and Pampusch et al. (2003) on days 0 (before implantation), 14, 28 (before 
ractopamine was fed), 42 and 56.  Biopsies on days 0, 28 and 56 were collected from the right 
side and on days 14 and 42 from the left side, with sampling sites being initially at the last rib 
and moving 5 cm anterior to the previous site.   
RNA isolation 
Muscle biopsy samples (0.5 g) from each steer were homogenized in 10 ml of a 5 M 
guanidine thiocyanate, 50 mM Tris-HCl, 25 mM EDTA, 0.5% lauryl sarcosine and 1% β-
mercaptoethanol solution (Solution D), followed by rapid freezing in liquid nitrogen and storage 
at −80 °C for later RNA isolation.  Total RNA was isolated as described by Dunn et al. (2003) 
and Pampusch et al. (2003).  Samples were treated with DNase to remove any contaminating 
genomic DNA using a commercially available kit (DNA-free
®
; Ambion, Austin, TX, USA).  The 
concentration of RNA was determined by absorbance at 260 nm.  Electrophoresis of total RNA 
through a 1% agarose-formaldehyde gel followed by ethidium bromide staining to allow 
visualization of 28S and 18S ribosomal RNA (rRNA) was used to assess the integrity of RNA.  
One microgram of total RNA was then reverse-transcribed to produce the first-strand 
complementary DNA (cDNA) using TaqMan
®
 reverse transcriptase (Applied Biosystems, Foster 
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City, CA, USA) following the protocol recommended by the manufacturer.  Random hexamers 
were used as primers in cDNA synthesis.  
Day 56 muscle and liver samples 
Steers were killed by administration of  sodium pentobarbital anesthesia followed by 
exsanguination in groups of two steers from the same block on days 56, 57 and 58.  All steers 
received ractopamine until harvested.  Following exsanguination, M. semimembranosus and 
liver samples were collected; these samples are referred to as day 56 samples throughout this 
paper.  Using sterile techniques, 50 g of M. semimembranosus and liver were dissected, rapidly 
frozen in liquid nitrogen and stored at −80 °C for subsequent RNA isolation.  The RNA was 
isolated from liver samples by using the RNeasy
®
 Mini Kit (Qiagen; Valencia, CA, USA).  The 
RNA was isolated from M. semimembranosus samples by using TRI REAGENT™ (Sigma; St. 
Louis, MO, USA).  Methods for determining RNA concentration and RNA integrity and for 
synthesizing cDNA were as described above.  
Real-time polymerase chain reaction 
Real-time quantitative-polymerase chain reaction was used to measure the quantity of 
mRNA for β1-, β2- and β3-adrenergic receptors, IGF-I (Class 1) and 18S rRNA in total RNA 
isolated from M. longissimus and M. semimembranosus.  The quantity of mRNA for IGF-I 
(Class 1) and 18S rRNA was measured in total RNA isolated from liver.  Measurement of the 
relative quantity of cDNA was conducted using TaqMan
®
 Universal PCR Master Mix (Applied 
Biosystems), 900 nM of the appropriate forward and reverse primers, 200 nM of the appropriate 
TaqMan
®
 detection probe and 1 µl of the cDNA mixture.  Sequences for primers and probes for 
IGF-I and β1-, β2- and β3- receptors are presented in Table 3.2.  The primers for IGF-I were 
designed to estimate Class 1 IGF-I mRNA.  Specifically, primers for IGF-I spanned exon 1 and 
exon 3 which estimated only Class 1 IGF-I mRNA.  Commercially available eukaryotic 18S 
rRNA primers and probes were used as an endogenous control (Applied Biosystems; Genbank 
Accession no. X03205).  Assays were performed in an ABI Prism
®
 7000 sequence detection 
system (Applied Biosystems) using thermal cycling parameters recommended by the 
manufacturer (50 cycles of 15 sec at 95 °C and 1 min at 60 °C).  Relative expressions of mRNA 
for β1-, β2- and β3-receptors and IGF-I were normalized to the 18S rRNA endogenous control 
and expressed in arbitrary units. 
Statistical analyses 
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Data were analyzed using the MIXED procedure of SAS System for Windows Release 
8.1 (SAS Inst. Inc., Cary, NC, USA).  The model contained the effects of implant, ractopamine, 
day within ractopamine, implant × ractopamine, and implant × day within ractopamine.  Block 
and block × implant were included as random variables. For nitrogen retention data, pretreatment 
values were included as a covariate.  Treatment means were computed using the LSMEANS 
option.  The LSD procedure was used to separate means.   
Results 
Nitrogen retention and diet digestibility 
Data for nitrogen retention and diet digestibility are presented in Table 3.3.  Dry matter 
digestibility was increased by ractopamine.  Ractopamine decreased nitrogen intake, fecal 
nitrogen output and urinary urea nitrogen output relative to controls.  Urinary nitrogen output 
and urinary ammonia nitrogen output were decreased by implantation and by feeding 
ractopamine to control steers, but were not affected when ractopamine was fed to implanted 
steers (significant implant  ractopamine interactions).  Similarly, nitrogen retention was 
increased by implantation during the initial 28 days of the study and by feeding ractopamine to 
control steers, but was not affected by feeding ractopamine to implanted steers (significant 
implant  ractopamine interaction).  
Blood metabolites 
Data for blood metabolites are presented in Fig. 3.2.  Plasma urea concentrations were 
similar among treatments.  Ractopamine tended to decrease plasma glucose concentrations, 
although the change was only 4%.  Serum insulin concentrations were not affected by 
implantation, but tended (p = 0.13) to be decreased by ractopamine with the decrease being more 
dramatic in the implanted steers.  Serum IGF-I concentrations were increased by implantation, 
whereas ractopamine tended to decrease serum IGF-I concentrations. 
Messenger RNA expression in M. longissimus, M. semimembranosus and liver 
Implantation tended (p = 0.16) to increase IGF-I mRNA expression in M. longissimus 
(Fig. 3.3), whereas ractopamine decreased IGF-I mRNA expression in M. longissimus in all 
steers.  Messenger RNA expression of IGF-I in M. semimembranosus also tended to be greater 
in implanted steers than in control steers (Table 3.4).  Implantation tended to increase hepatic 
IGF-I mRNA expression compared to control steers (Table 3.4).  Data for mRNA expression of 
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β1-, β2- and β3- receptors in M. longissimus are presented in Fig. 3.3.  Implantation had no effect 
on mRNA expression of β1-, β2- and β3-receptors in M. longissimus, but expression of β1- and 
β2-receptor mRNA was decreased by ractopamine.  Implantation did not affect β1- or β3-receptor 
mRNA expression in the M. semimembranosus (Table 3.4), but β2-receptor mRNA expression 
tended to be increased by implantation. 
Discussion 
A change in digestibility in response to ractopamine feeding was observed in our study.  
Brikas (1989) suggested that β-agonists act on β-receptors in the gastrointestinal tract and 
decrease gut contractions.  Subsequently, retention time of digesta is increased resulting in 
increased digestion.  Ractopamine decreased nitrogen intake, but the decrease in nitrogen intake 
was a result of a lesser concentration of nitrogen in the individual feed ingredients when 
ractopamine was fed and not a change in dry matter intake.   
As shown in Fig. 3.1, implantation increased nitrogen retention within the first 4 days 
after implantation.  When ractopamine feeding was initiated, it led to rapid increases in nitrogen 
retention within the first 4 days, but the increase was more dramatic in the control steers than in 
the implanted steers such that the difference in nitrogen retention between the control and 
implanted steers was less when ractopamine was fed (Fig. 3.1).  Lobley et al. (1985) 
demonstrated that nitrogen retention in steers implanted with 140 mg TBA/ 20 mg E2 was more 
than double that of nonimplanted steers with large responses observed even 11 weeks after 
implantation.  Similar to our responses to ractopamine, Anderson et al. (1989) reported a 51% 
increase in nitrogen retention in steers (287 kg) fed diets containing 100 ppm ractopamine.  Our 
data support previous findings that implantation and ractopamine increase nitrogen retention in 
steers. 
Steers implanted with 140 mg TBA/ 28 mg E2 demonstrated a 30% decrease in plasma 
urea concentrations compared to nonimplanted steers (Hongerholt et al., 1992).  In contrast, urea 
concentrations were not affected by treatment in our study.  Although insulin concentrations 
were not significantly affected by ractopamine, implanted steers demonstrated a 66% decrease in 
concentrations when ractopamine was fed.  Experiments conducted by O’Connor et al. (1991) 
demonstrated decreases in serum insulin concentrations in lambs fed 10 ppm cimaterol for 6 
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weeks.  Although large changes in insulin concentrations were observed, glucose concentrations 
were not altered and this could likely be a result of changes in glucose sensitivity.    
Johnson et al. (1996b) reported in finishing steers that implantation with a TBA/E2 
implant increased circulating IGF-I through 115 days compared to non-implanted controls.  In 
our study, steers were implanted for a total of 56 days and were implanted for 28 days before 
ractopamine feeding.  Similar to our results, Beermann et al. (1987) reported 46.5 and 21.5% 
decreases in serum IGF-I concentrations in lambs fed cimaterol for 6 and 12 weeks compared to 
lambs not fed cimaterol.  The majority of IGF-I in circulation is thought to be derived from liver 
production and, therefore, decreases in IGF-I concentrations in the steers fed ractopamine in our 
study could be attributed to ractopamine affecting hepatic IGF-I synthesis or release.     
The possibility exists that responses to ractopamine feeding resulted from confounding 
with time.  The temporal patterns of serum IGF-I (Fig. 3.2) and of M. longissimus IGF-I mRNA 
expression (Fig. 3.3), however, suggest a rather specific response after the initiation of 
ractopamine feeding without subsequent decreases between days 42 and 56, which would be 
expected if decreases were related to passage of the time.  Johnson et al. (1996b) observed that 
serum IGF-I decreased over time in both implanted and control steers, but their cattle were 
yearling steers nearing their physiological end-point, whereas our steers were well less than half 
of their mature weight.  Thus, an age-related depression in IGF-I would be unlikely to explain 
the decreases in serum IGF-I and mRNA expression of IGF-I by M. longissimus in our 
experiment. 
Finishing steers implanted with TBA/E2 for 40 days had 68% more IGF-I mRNA in M. 
longissimus than did control steers (Johnson et al., 1998a).  Pampusch et al. (2003) reported that 
steers implanted with TBA/E2 had significantly greater IGF-I mRNA in M. longissimus on days 
14 and 28 compared to steers not implanted.  These data are in agreement with our findings that 
TBA/E2 will elevate IGF-I mRNA expression in M. longissimus of steers.  In contrast to 
implants, steers fed ractopamine in our study demonstrated an opposite effect in that IGF-I 
mRNA expression was decreased.  Sissom et al. (2005) reported that heifers implanted with 200 
mg TBA/20 mg E2 on day 0 and then fed ractopamine starting on day 154 had significantly less 
IGF-I mRNA abundance in the M. semimembranosus when ractopamine was fed.  However, in 
heifers initially implanted with 80 mg TBA/8 mg E2 and re-implanted with 200 mg TBA 96 days 
prior to ractopamine feeding, IGF-I mRNA expression in M. semimembranosus was not affected 
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by ractopamine being fed for 28 days (Sissom et al., 2005).  Our samples of M. 
semimembranosus collected on day 56 demonstrated a pattern for IGF-I mRNA expression 
similar to that in M. longissimus.  Because all steers received ractopamine during the final 28 
days of the experiment, only the effect of implant could be evaluated in M. semimembranosus. 
Hepatic IGF-I mRNA abundance was greater in implanted steers, which matches the 
response to implantation for circulating concentrations of IGF-I.  These data support that hepatic 
production of IGF-I was a major contributor to circulating concentrations.  Although mRNA 
expression is not always directly correlated with that translated, mRNA expression of IGF-I 
presented a pattern consistent with serum IGF-I and with previously observed effects of TBA/E2 
implants on IGF-I mRNA (Pampusch et al., 2003).  Increases in local tissue production and/or 
circulating concentrations of IGF-I can increase muscle growth in implanted animals.  From our 
data, however, it appears that increases in IGF-I are not responsible for enhanced growth with 
ractopamine; decreases in local tissue production as well as circulating concentrations of IGF-I 
were observed in response to ractopamine.  Therefore, the increases in growth observed in 
response to ractopamine would seem to involve other mechanisms.  It is possible, however, that 
IGF-I, although lesser in concentration, is more active in ractopamine-treated cattle due to 
changes in IGF binding proteins (IGFBP) or in the type I IGF-I receptor.  Awede et al. (2002) 
reported that clenbuterol, a β2-agonist, fed to rats increased mRNA expression of IGF-I and 
IGFBP-4 in the M. soleus, but decreased circulating concentrations of IGF-I.  The association of 
IGFBP-4 with IGF-I could alter its half-life and biological activity.  We did not measure any of 
the IGFBP and, therefore, this suggestion is speculation.  Yimlamai et al. (2005) reported that 
clenbuterol fed to rats for 2 weeks decreased protein expression of IGF-I in the M. plantaris, but 
did not affect protein expression of IGF-I in the M. tibialis anterior.  These data support that 
decreases in IGF-I could be mediated by β-agonist compounds, like ractopamine. 
Sissom et al. (2005) reported that, in the M. semimembranosus of implanted heifers, 
ractopamine did not affect β1-receptor mRNA abundance and tended to increase β2-receptor 
mRNA expression.  These data conflict with our findings that ractopamine decreased abundance 
of both β1- and β2-receptor mRNA in M. longissimus.  Differences between our study and that of 
Sissom et al. (2005) include the implant strategy and age and gender of the cattle.  Yearling 
steers implanted with 80 mg TBA/16 mg E2 and re-implanted with 120 mg TBA/24 mg E2 
between 122 and 164 days before ractopamine feeding had increased β2-receptor mRNA 
  67 
expression in M. semimembranosus when fed ractopamine for 28 days compared to steers that 
did not receive ractopamine (Winterholler et al., 2006).   
Chronic exposure to β-agonists is suggested to lead to desensitization of the β-receptors 
(Hausdorff et al., 1990) which is consistent with the decreases in β1- and β2-receptor mRNA that 
we observed in response to ractopamine, although decreases in response to ractopamine were not 
greater after 28 days than after 14 days of feeding.  In our study β1- and β2-receptor mRNA 
abundance was suppressed by ractopamine indicating a down-regulation of the receptors mRNA 
levels.  
Our results demonstrate that implanting steers with TBA/E2 has a stimulatory effect on 
serum IGF-I and IGF-I mRNA expression in the M. longissimus.  In contrast, ractopamine 
appears to have a different mode of action, as demonstrated by decreases in serum IGF-I and in 
IGF-I mRNA expression by the M. longissimus.  Both implanting steers and feeding 
ractopamine can improve growth, but, in our model with Holstein steers, a combination of the 
two growth promotants was less than additive for increasing nitrogen retention. 
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Table 3.1 Diet Composition 
 
Ingredient              % of DM 
Dry rolled corn  62.0 
Expeller soya bean meal  20.0 
Alfalfa hay  15.0 
Limestone  1.4 
Trace mineral salt
*
  0.5 
Dicalcium phosphate  0.22 
Vitamin premix
†
  0.15 
Sulfur  0.05 
Rumensin
® ‡
  0.017 
Tylan
® §
  0.0125 
 * 
Composition (minimum guarantee, %): NaCl (95 to 99); Mn  
(> 0.24); Cu (> 0.032); Zn (> 0.32); I (> 0.007); and Co (> 0.4). 
† 
Provided 4,400 IU of vitamin A; 2,200 IU of vitamin D; and 35 IU of  
  vitamin E per kg of diet DM. 
‡ 
Provided 30 mg of monensin/kg of diet DM. 
 § 
Provided 11 mg of tylosin/kg of diet DM. 
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Table 3.2 Sequence of bovine specific polymerase chain reaction primers and TaqMan probes used for determination of 
expression of mRNA of IGF-I, and β1-, β2-, and β3-adrenergic receptors    
Primer Sequence (5’ to 3’) 
IGF-I (Accession # X15726)  
   Forward TGTGATTTCTTGAAGCAGGTGAA 
   Reverse AGCACAGGGCCAGATAGAAGAG 
   TaqMan probe 6FAM-GCCCATCACATCCTCCTCGCA-TAMRA 
β1-adrenergic receptor (Accession # AF188187)  
   Forward GTGGGACCGCTGGGAGTAT 
   Reverse TGACACACAGGGTCTCAATGC 
   TaqMan probe 6FAM-CTCCTTCTTCTGCGAGCTCTGGACCTC-
TAMRA β2-adrenergic receptor (Accession # NM_174231)  
   Forward CAGCTCCAGAAGATCGACAAATC 
   Reverse CTGCTCCACTTGACTGACGTTT 
   TaqMan probe 6FAM-AGGGCCGCTTCCATGCCC-TAMRA 
β3-adrenergic receptor (Accession # X85961)  
   Forward AGGCAACCTGCTGGTAATCG 
   Reverse GTCACGAACACGTTGGTCATG 
   TaqMan probe 6FAM-CCCGGACGCCGAGACTCCAG-TAMRA 
  
7
3
 
Table 3.3 Effects of steroidal implantation and feeding ractopamine on nitrogen retention and diet digestibility in growing steers 
 No ractopamine  
Ractopamine-HCl, 
200 mg/day  p-value 
Item Control Implant  Control Implant SEM Implant Ractopamine I × R 
Nitrogen, (g/day) 
         
   Dietary intake 143.2 140.4  139.6 135.6 3.9 0.65 < 0.001 0.42 
   Faecal 35.2 35.4  29.1 29.9 2.9 0.93 < 0.001 0.73 
   Urinary 77.2
z
 60.8
x
  71.2
y
 60.2
x
 4.0 0.07 0.003 0.02 
      Ammonia 6.9
y
 3.1
x
  4.7
x
 4.1
xy
 1.2 0.40 0.31 0.006 
      Urea 63.2 49.9  60.6 46.7 4.3 0.19 0.02 0.81 
   Retained 30.4
x
 44.6
z
  39.0
y
 45.9
z
 1.4 0.07 < 0.001 0.002 
Dry matter digestibility (%) 76.9 77.7  79.0 80.2 1.9 0.61 0.0002 0.75 
Each response represents an average over 28 days.  
Means values in rows not bearing a common superscript letter differ, p < 0.05. 
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Table 3.4 Effects of steroidal implantation on mRNA expression in M. semimembranosus and 
liver of ractopamine-treated steers 
 Item Control  Implant SEM  p-value 
M. semimembranosus, mRNA (Arbitrary Units)   
  β1 adrenergic receptor        47         23        13 0.32 
  β2  adrenergic receptor 16 305  29 246    8965 0.08 
  β3 adrenergic receptor        78         24        34 0.36 
  IGF-I      956     3288      792 0.11 
Liver, mRNA      
  IGF-I 37 252  78 554 19 536 0.16 
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Figure 3.1 Effects of implantation and ractopamine on nitrogen retention over time in Holstein 
steers.  
Each value represents nitrogen retention over a 4-day period (n=3).  Days listed represent first 
day of collection.  Filled symbols represent time-points without ractopamine, whereas open 
symbols represent times-points when ractopamine was feed.  R = Ractopamine, I = Implant. 
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Figure 3.2 Effects of implantation and ractopamine on blood metabolites over time in Holstein 
steers.  
For each point, n=3.  Filled symbols represent time-points without ractopamine, whereas 
open symbols represent times when ractopamine was fed.  Blood samples were collected 2 h 
after the morning feeding.  R = Ractopamine, I = Implant. 
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Figure 3.3 Effects of implantation and ractopamine on M. longissimus mRNA expression over 
time in Holstein steers.   
For each point, n=3.  Filled symbols represent time-points without ractopamine, whereas open 
symbols represent times when ractopamine was fed.  R = Ractopamine. 
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Abstract 
Our experiment evaluated growth-related responses to ractopamine in steers and heifers.  
Sixteen Angus steers and 16 Angus heifers (493 kg) housed in individual pens were used in a 
randomized complete block design.  At 90 to 97 d prior to the experiment, steers were implanted 
with 120 mg trenbolone acetate and 24 mg estradiol-17β (Component TE-S) and heifers were 
implanted with 140 mg trenbolone acetate and 14 mg estradiol-17β (Component TE-H).  
Treatments were arranged as a 2 × 2 factorial and included: gender (steer vs. heifer) and 
ractopamine-HCl (0 or 200 mg/d) for the final 28 d.  Cattle were fed a diet based on steam-flaked 
corn once daily.  Blood and longissimus (LM) and biceps femoris (BF) biopsy samples were 
collected on d 0 (prior to ractopamine feeding) and after 14 and 28 d of ractopamine feeding.  
Serum insulin-like growth factor (IGF)-I concentrations were greater in steers than heifers (P < 
0.001), and steers demonstrated greater IGF-I mRNA expression in BF than heifers (P = 0.05).  
In vitro protein synthesis rates tended to be greater in LM of steers than in LM of heifers (P = 
0.10).  Ractopamine decreased serum IGF-I concentrations in heifers on d 14, but increased 
serum IGF-I concentrations in steers on d 28 (gender × ractopamine × day interaction; P = 0.03).  
Ractopamine did not affect mRNA expression of IGF-I in BF (P = 0.21) or in LM (P = 0.22). 
Expression of IGFBP-3 and -5 mRNA in LM and BF were not affected by ractopamine (P ≥ 
0.42).  Ractopamine decreased in vitro protein degradation rates (P = 0.03) and numerically 
increased calpastatin mRNA expression in LM (P = 0.23), but numerically increased protein 
degradation rates in BF (P = 0.19).  Ractopamine decreased myosin heavy chain IIA mRNA 
expression in BF (P = 0.04).  Ractopamine decreased β2-receptor mRNA expression in LM of 
steers on d 14, but numerically increased it in steers on d 28; in contrast expression of β2-receptor 
mRNA in LM of heifers was not affected by ractopamine (gender × ractopamine × day 
interaction; P = 0.03).  The effects of ractopamine on protein degradation seem to be somewhat 
different between LM and BF.  Ractopamine does not appear to greatly impact muscle 
expression of mRNA for IGF-I or for the IGFBP-3 and -5. 
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Introduction 
Ractopamine-HCl is a β-adrenergic agonist that is approved for use in finishing cattle.  
Ractopamine administration elicits responses through β-adrenergic receptors (βAR; β1 and β2) 
and results in increased muscle mass with minimal effects on adipose tissue (Mersmann, 1998).  
Ractopamine-HCl fed at 200 mg/d for the final 28 d can improve ADG and G:F by 17 and 18% 
(Laudert et al., 2004) and by 15 and 17% (Gruber et al., 2007) in finishing steers and by 18 and 
15% (Schroeder et al., 2005b) and by 11 and 12% (Laudert et al., 2007) in finishing heifers.  In 
contrast, Quinn et al. (2006) reported no change in carcass gain, DMI, and carcass efficiency 
when non-implanted heifers were fed 200 mg/d ractopamine-HCl for the final 28 d.  Sissom et al. 
(2007) demonstrated 2.2 and 4.0% improvements in ADG and G:F with no effect on DMI over 
the entire 178 to 187 d feeding period in finishing heifers fed 200 mg/d ractopamine-HCl for the 
final 28 d.  Hot carcass weight has been increased by 8 (Winterholler et al., 2007), 6 (Laudert et 
al., 2004), and 5.5 kg (Gruber et al., 2007) in feedlot steers.  In feedlot heifers, HCW was 
increased by 4.6 (Laudert et al., 2007) and 2.9 kg (Schroeder et al., 2005b).   
Although, improvements in growth and carcass performance are observed in feedlot 
steers and heifers, the responses in heifers seem more variable, suggesting that ractopamine may 
be acting somewhat differently in heifers than in steers.  Our objectives were to determine the 
effects of feeding ractopamine to finishing steers and heifers on skeletal muscle protein turnover 
and gene expression, and to determine if responses differed between steers and heifers.     
 
Materials and Methods 
Procedures for this study were approved by the Kansas State University Institutional 
Animal Care and Use Committee. 
Animals   
Sixteen Angus steers and 16 Angus heifers were used in a randomized complete block 
design experiment to evaluate the responses of steers and heifers to ractopamine feeding.  Cattle 
originated from 2 different sires and were fed similarly for 1 mo prior to arrival.  Cattle were 
received 100 to 107 d prior to initiation of the experiment, grouped by gender in 2 pens, and 
transitioned from a 60% concentrate:40% roughage diet to a 90% concentrate:10% roughage diet 
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within the first 30 d.  Thereafter, all cattle were fed a common diet based on steam-flaked corn 
for ad libitum consumption for 70 to 77 d prior to initiation of the trial.  Ten days after arrival, 
corresponding to 90 to 97 d prior to cattle starting on the trial, steers were implanted with 120 
mg TBA and 24 mg E2 (Component TE-S, Vet Life, West Des Moines, IA) and heifers were 
implanted with 140 mg TBA and 14 mg E2 (Component TE-H, Vet Life).  Steers and heifers 
averaged 15.6 and 15.3 mo of age, respectively, when started on trial, and as a group the catle 
graded 68% USDA Choice and 45% USDA Yield grade 2 and 50% USDA Yield grade 3.    
Overall Design 
Treatments included gender (steer or heifer) and ractopamine-HCl (0 or 200 mg/d; 
Optaflexx; Elanco Animal Health, Greenfield, IN).  Steers and heifers were blocked (8 blocks 
with each containing 2 steers and 2 heifers) based on BW and ADG during the 90 d prior to the 
start of the experiment.  To accomplish blocking, cattle were sorted into the heaviest 8 and the 
lightest 8 animals within each gender.  Within gender and BW group, cattle were sorted into 
groups of 2 animals based on ADG.  Groups of 4 pens were assigned to blocks.  Within each 
block of 4 pens, treatments were randomly assigned to pens.  Cattle within each block were then 
assigned to treatment.  The gender was predetermined, so only the ractopamine treatment was 
randomized between the 2 cattle of the same gender within each block, and this was 
accomplished by the flip of a coin.  The cattle assigned to each treatment were then placed in the 
appropriate pen within their block.  All cattle were fed and housed individually in 4.5 × 1.5 m 
pens for 7 to 8 d prior to initiation of the experiment and were given ad libitum access to water 
and feed (Table 4.1) for 28 d, which represents both the shortest feeding time for which 
ractopamine usage is labeled as well as the most typical feeding period for ractopamine by the 
feedlot industry.  Cattle were fed once daily at 1600 with bunk management designed to yield 
slick bunks at feeding.   
Due to the number of cattle and logistics of the procedures imposed, complete blocks of 
steers and heifers were started on trial staggered over time.  Trial initiation for blocks 1 and 2 
occurred 1 d prior to that for blocks 3 and 4, 7 d prior to that for blocks 5 and 6, and 8 d prior to 
that for blocks 7 and 8.  Beginning at 0630 on each sampling day, a portable chute was placed in 
front of each pen and cattle were placed into the chute.  Cattle were bled, and biopsy samples 
were collected from the biceps femoris (BF) and LM.  Sample collection occurred on d 0 before 
initiation of ractopamine feeding, and on d 14 and 28 of ractopamine feeding.  After sample 
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collection on d 0 (before initiation of ractopamine feeding) and on d 28 of ractopamine feeding 
for each block, cattle were weighed at 1100.  For 2 blocks, cattle assigned to the ractopamine 
treatment mistakenly received ractopamine on the day before the initial sampling; their d-0 data 
were not used for statistical analysis (see below), and samples collected after 15 and 29 d of 
ractopamine feeding were considered equivalent to those collected after 14 and 28 d of 
ractopamine feeding.     
Blood Samples   
Jugular blood samples were collected into vacuum tubes (Becton Dickinson, Franklin 
Lakes, NJ) containing sodium heparin, immediately placed on ice, and centrifuged for 20 min at 
1,000 × g to obtain plasma.  Blood was also collected into vacuum tubes without additives, 
allowed to clot for 24 h at 4°C, and then centrifuged for 20 min at 1,000 × g to obtain serum.  
Plasma samples were stored ( 20°C) for later analysis of glucose (Gochman and Schmitz, 1972) 
and urea (Marsh et al., 1965).  Sera were stored ( 20°C) for later analysis of insulin (RIA kit, 
DSL-1600; Diagnostic Systems Laboratories, Webster, TX; intra-assay CV = 4.7%, assay 
sensitivity = 0.00838 ng/mL; Greenwood et al., 2001) and insulin-like growth factor (IGF)-I 
(IGF-I coated-tube immunoradiometric assay kit, DSL-5600; Diagnostic Systems Laboratories; 
intra-assay CV = 4.3%, assay sensitivity = 5.0 ng/mL; Greenwood et al., 2001).  
Muscle Biopsies 
Biopsy samples were collected from the BF and LM (Dunn et al., 2003; Pampusch et al., 
2003) for measuring in vitro protein synthesis and degradation and gene expression.  Biopsies on 
d 0 and 28 were collected from the left side and on d 14 from the right side, with LM sampling 
sites being initially at the last rib and moving 5 cm anterior to the previous site and with BF 
sampling sites being initially mid-way between the trochanter major of the femur and the tuber 
ischii and moving 5 cm ventral to the previous site.  
In Vitro Protein Synthesis  
In vitro protein synthesis rates were determined as described by Greig et al. (1986) from 
biopsy samples collected on d 0, 14, and 28 from the BF and LM.  Samples (150 to 300 mg) 
were blotted on sterile gauze and placed in pre-incubation medium for transport to the lab.  The 
pre-incubation media contained Krebs-Ringer bicarbonate buffer, saturated with 95% O2:5% 
CO2 by bubbling for 30 min, 10 mM glucose, 0.1 IU porcine insulin/mL, and 20 AA (mM; Ala 
4.5, Arg 2.0, Asn 0.7, Asp 0.35, Cys 0.7, Glu 2.0, Gln 3.5, Gly 4.0, His 0.8, Ile 1.0, Leu 1.7, Lys 
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4.0, Met 0.7, Phe 0.8, Pro 1.8, Ser 2.8, Thr 3.0, Trp 0.7, Tyr 0.7, and Val 2.0).  For each muscle 
within each animal, 20 to 40 mg of tissue were placed into each of 5 incubation tubes containing 
3.0 mL of incubation medium, re-gassed with 95% O2:5% CO2, and incubated for 3 h at 37°C in 
a metabolic shaker bath.  The incubation media contained the pre-incubation media plus 1.8 µCi 
L-[
3
H]-tyrosine.  Following incubation, tissue samples were removed from the media, blotted, 
weighed, frozen in liquid N2, and stored at -20°C.  Media were frozen in liquid N2 and stored at -
20°C.    
Muscle samples were homogenized (Tissue Tearor; Biospec Products, Inc., Bartlesville, 
OK) in 2.5 mL of 10 mM potassium phosphate buffer (pH 7.4 at 0 to 5°C).  Protein was 
precipitated from 2.0 mL of homogenate with 1 mL of 30% (wt/vol) trichloroacetic acid (TCA) 
at 0 to 5°C and centrifuged at 11,000 × g for 10 min.  The protein pellet was washed twice with 
10% (wt/vol) TCA and dissolved in 1.0 mL of tissue solubilizer (NCS-II Tissue Solubilizer, 
Amersham Biosciences, Little Chalfont Buckinghamshire, England) at 65°C for 30 min.  The 
solution was poured into a scintillation vial with 15 mL of scintillation cocktail (ScintiSafe Plus 
50%, Fisher Scientific, Hanover Park, IL).  Samples were allowed to stand overnight in low 
lighting to reduce chemiluminescence before being counted in a scintillation counter.  The 
medium (3.0 mL) was acidified with 1.0 mL of 40% TCA (wt/vol) at 0 to 5°C and centrifuged at 
11,000 × g for 10 min.  An aliquot of the supernatant was analyzed for tyrosine concentration as 
described by Waalkes and Udenfriend (1957), and a 1.0-mL aliquot was counted for 
radioactivity.   
Protein synthesis rates were estimated by 
3
H-Tyr incorporation into protein.  The 
equation utilized to calculate synthesis rates was: protein synthesis rate = [dpm in protein / 
specific activity of free Tyr, dpm/µg] / (wet tissue weight, g × 3 h).  Concentrations of Tyr (0.7 
mM) were 10 times that of bovine plasma and, therefore, Tyr was assumed to equilibrate 
between the medium and intracellular precursor pool.  Consequently, Tyr specific activity in the 
medium was used as the specific activity of the precursor pool.  The median value from the 5 
replicates was used for statistical analysis.      
In Vitro Protein Degradation  
In vitro protein degradation rates were determined as described by Greig et al. (1986) 
from biopsy samples collected on d 0, 14, and 28 from the BF and LM.  Samples (150 to 300 
mg) were blotted on sterile gauze and placed in pre-incubation medium for transport to the lab.  
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The pre-incubation medium contained Krebs-Ringer bicarbonate buffer with 10 mM glucose.  
For each muscle within each animal, 20 to 40 mg of tissue were placed into each of 6 incubation 
tubes containing 3.0 mL of incubation medium (pre-incubation media and 0.5 mM 
cycloheximide) and re-gassed with 95% O2:5% CO2. Three incubation tubes were immediately 
frozen in liquid N2 and were used for measuring background concentrations of free Tyr.  Three 
tubes were incubated for 3 h at 37°C in a metabolic shaker bath.  Following incubation, samples 
were frozen in the media in liquid N2 and stored at -20°C.   
Muscle samples were homogenized in medium.  An aliquot of the homogenate was 
assayed for protein concentration via Coomassie Blue Protein Assay Kit (Pierce, Rockford, IL).  
Protein was precipitated from 1.0 mL of homogenate with 0.5 mL of 30% TCA (wt/vol) at 0 to 
5°C and centrifuged at 11,000 × g for 10 min.  A 1.0-mL aliquot of the supernatant was analyzed 
for Tyr concentration (Waalkes and Udenfriend, 1957). 
Protein degradation rates were estimated by Tyr release.  Cycloheximide was included in 
the incubation media to inhibit protein synthesis, thereby preventing re-utilization of released 
Tyr.  The equation utilized to calculate degradation rates was : protein degradation rate = [(Tyr in 
incubated samples/(mg protein × 0.025)) – (Tyr in un-incubated samples/(mg protein × 0.025))] / 
3 h, where 0.025 is the fraction of skeletal muscle as Tyr (Lobley et al., 1980) and 3 h is the 
incubation time.  
RNA Isolation 
Muscle biopsy samples (2 g) were rapidly frozen in liquid N2 and stored at −80°C for 
subsequent RNA isolation.  Total RNA was isolated from BF and LM samples as described by 
Dunn et al. (2003) and Pampusch et al. (2003).  The concentration of RNA was determined by 
absorbance at 260 nm.  To verify the integrity of the RNA, visualization of the 28S and 18S 
ribosomal RNA (rRNA) was accomplished with a 2100 Bioanalyzer (Agilent, Foster City, CA).  
One microgram of total RNA was reverse-transcribed to produce the first-strand complementary 
DNA (cDNA) using TaqMan reverse transcriptase (Applied Biosystems, Foster City, CA) 
following the protocol recommended by the manufacturer.  Random hexamers were used as 
primers in cDNA synthesis. 
Real Time PCR  
Real-time quantitative-PCR was used to measure the quantity of mRNA for β1-, β2-, and 
β3-adrenergic receptors, IGF-I (Class 1), IGFBP-3 and -5, calpastatin, myosin heavy chain 
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(MHC) IIA, and 18S rRNA in total RNA isolated from BF and LM.  Measurement of the relative 
quantity of cDNA was conducted using TaqMan Universal PCR Master Mix (Applied 
Biosystems), 900 nM of the appropriate forward and reverse primers, 200 nM of the appropriate 
TaqMan detection probe, and 1 µL of the cDNA mixture.  Sequences for primers and probes are 
presented in Table 4.2.  The primers for IGF-I spanned exon 1 and exon 3 and were designed to 
measure Class 1 IGF-I mRNA.  Commercially available eukaryotic 18S rRNA primers and 
probes were used as an endogenous control (Applied Biosystems; Genbank Accession no. 
X03205).  Assays were performed in an ABI Prism 7000 sequence detection system (Applied 
Biosystems) using thermal cycling parameters recommended by the manufacturer (40 cycles of 
15 sec at 95°C and 1 min at 60°C).  Relative expressions of mRNA for β1-, β2-, and β3-
adrenergic receptors, IGF-I (Class 1), IGFBP-3 and -5, calpastatin, and MHC IIA were 
normalized to the 18S rRNA endogenous control and expressed in arbitrary units.  Samples with 
a 18s rRNA value for thermal cycles below 10 and above 13 were re-run using newly 
synthesized cDNA for the PCR reactions.  Any samples associated with a gene arbitrary unit 
value grossly outside the typical range were re-run using newly synthesized cDNA for the PCR 
reactions.  For any re-run samples remaining outside the aforementioned ranges, RNA was re-
isolated, cDNA synthesized, and the PCR reaction was re-run.  One sample from d 0 was 
misplaced and, therefore, the data were missing.     
DNA, RNA, and Protein Concentrations 
Concentrations of DNA, RNA, and protein were determined in LM and BF biopsy 
samples collected on d 28.  Approximately 300 mg of tissue was ground into powder using a 
mortar and pestle submerged in liquid N2.  One hundred milligrams of ground sample, in 
duplicate, was used to isolate RNA as described previously.  Concentration of RNA was 
determined by absorbance at 260 nm, and the highest value of duplicate samples was used.   
Twenty five milligrams of ground sample, in duplicate, were used to isolate DNA via 
DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA; Blin and Stafford, 1976).  To determine 
DNA concentration, 100 µL of sample was mixed with phosphate buffer containing 
bisbenzimidazole (compound H 33258) to a final concentration of 1 µg/mL as described by 
Labarca  and Paigen (1980).  Fluorescence was measured with a fluorimeter (HP 1046A 
Programmable Fluorescence Detector; Santa Clara, CA; excitation, 356 nm; emission, 458 nm) 
within 16 h of mixing.  The concentrations of DNA were determined by comparison to an 
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external standard curve of bovine calf thymus DNA in a range to 5.0 µg/mL.  The highest value 
of the duplicate samples was used.  For one heifer fed ractopamine for LM, analysis of muscle 
composition yielded unreasonable data, and therefore observations for this sample were excluded 
from statistical analysis.   
Ten milligrams of ground sample was placed into 500 µL of phosphate buffer (0.05 M 
Na2HPO4, 2 M NaCl, adjusted to pH 7.4) and homogenized with a polytron homogenizer.  
Protein concentrations were determined from an aliquot of the homogenate using the Coomassie 
Blue Protein Assay Kit (Pierce).    
Statistical Analysis  
Data were analyzed using the MIXED procedure of SAS System for Windows Release 
9.1 (SAS Inst. Inc., Cary, NC).  Performance and RNA, DNA, and protein concentration data 
were analyzed as a randomized complete block design.  The model contained the effects gender, 
ractopamine, and ractopamine × gender.  Block was included as a random effect.  All other data 
were analyzed as a randomized complete block design with repeated measures with d-0 values 
used as a covariate.  The model contained the effects of the covariate, gender, ractopamine, 
ractopamine × gender, day, ractopamine × day, gender × day, and ractopamine × gender × day. 
Block was included as a random effect.  The repeated statement included day as the repeated 
variable with animal as experimental unit and the covariance structure as unstructured.  To 
estimate missing values from d 0, values were predicted using the same model but without the 
covariate.  Because the covariates (d 0 values) would remove most of the effects of gender, 
which was fixed before the d 0 measures, data were analyzed for the main effect of gender 
without the use of covariates as well as without inclusion of predicted d 0 values.  Treatment 
means were computed using the LSMEANS option, and pair-wise t-tests were used to separate 
means when interactions were significant.    
Results and Discussion 
Effects of Gender and Ractopamine on Performance    
Performance data for steers and heifers are presented in Table 4.3.  Heifers fed 
ractopamine consumed 16% less DM than control heifers, but in steers there were no differences 
in DMI in response to ractopamine (gender × ractopamine interaction; P = 0.05).  Dry matter 
intake in finishing heifers generally is not affected by ractopamine (Chapter 2 of this thesis; 
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Schroeder et al., 2005b; Sissom et al., 2007).  Gruber et al. (2007) observed no change in DMI in 
feedlot steers administered ractopamine.  Heifers assigned to the ractopamine treatment 
consumed less feed relative to the other cattle for the week prior to the study (7.7, 6.3, 6.7, and 
7.2 kg for control heifers, heifers fed ractopamine, control steers, and steers fed ractopamine), 
suggesting that the low DMI for ractopamine-fed heifers probably does not reflect a response to 
ractopamine.     
The BW of heifers on d 0 and 28 were less than the steers (P < 0.001).  The final BW (d 
28) for steers and heifers were not affected by ractopamine feeding.  Daily gains and G:F were 
not affected by ractopamine or gender, although ractopamine numerically increased ADG (16%) 
and G:F (21%) in steers.  Our ability to detect performance responses to ractopamine was limited 
by the unexpectedly low DMI of heifers fed ractopamine.  Gain efficiencies above maintenance 
were calculated (Table 4.3) because they are independent of DMI, and ractopamine tended (P = 
0.07) to increase G:F above maintenance by 20%, which is similar to improvements in G:F 
observed in other trials.  Schroeder et al. (2005a) demonstrated 20 and 21% increases in ADG 
and G:F in feedlot steers fed 20 ppm ractopamine for the final 28 to 42 d.  Gruber et al. (2007) 
reported 15 and 17% improvements in ADG and G:F in implanted finishing steers when fed 200 
mg/d ractopamine for the final 28 d.  Schroeder et al. (2005b) observed increases of 18 and 15% 
in ADG and G:F in finishing heifers fed 20 ppm ractopamine for the final 28 to 42 d.  Laudert et 
al. (2007) demonstrated 11 and 14% increases in ADG and G:F in implanted finishing heifers fed 
200 mg/d ractopamine for the final 28 d.  Implanted finishing heifers in response to feeding 200 
mg/d ractopamine for the final 28 d demonstrated 18% increases in ADG and G:F (Chapter 2 in 
this thesis).    
Effect of Gender      
Data for blood metabolites are presented in Table 4.4.  Steers tended to have greater 
plasma glucose concentrations than heifers (P = 0.08).  Plasma urea concentrations in steers were 
less (P = 0.003) than those in heifers.  Serum insulin concentrations were not affected by gender.  
Serum IGF-I concentrations were greater (P < 0.001) in steers than heifers.  Plouzek and Trenkle 
(1991) using non-implanted cattle demonstrated 20 and 43% greater serum IGF-I concentrations 
in steers than in heifers at 12 and 15 mo of age.  Because steers deposit more lean tissue than 
heifers at the end of the finishing period, lower plasma urea and greater serum IGF-I 
concentrations might be expected in steers compared to heifers.   
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Protein synthesis and degradation rates are presented in Table 4.4.  In LM, protein 
synthesis rates tended to be higher in steers compared to heifers (P = 0.10).   Protein synthesis 
rates in BF (P = 0.76) and protein degradation rates in BF and LM (P ≥ 0.42) were not affected 
by gender.   
Data for mRNA expression of IGF-I, IGFBP-3 and -5, MHC IIA, calpastatin, and β1-, β2-
, and β3- receptors in BF and LM are presented in Table 4.4.  In BF, steers demonstrated greater 
IGF-I mRNA expression than heifers (P = 0.05).  Steers demonstrated numerically greater 
mRNA expression of IGFBP-3 (P = 0.10) and -5 (P = 0.17) in LM compared to heifers.  
Calpastatin and MHC IIA mRNA expression in BF (P = 0.59) and LM (P = 0.22) were not 
affected by gender.  β1- and β2-receptor mRNA expression in BF and β1- and β3-receptor mRNA 
expression in LM were not affected by gender.  β3-receptor mRNA expression in BF (P = 0.08) 
and β2-receptor mRNA expression in LM (P = 0.11) tended to be greater in steers compared to 
heifers.  Greater amounts of β2-receptor mRNA may allow for steers to respond better than 
heifers to β-agonists such as ractopamine.   
Data for RNA, DNA, and protein concentrations and protein:DNA, protein:RNA, and 
RNA:DNA ratios are presented in Table 4.7.  No effect of gender on RNA, DNA, and protein 
concentration were observed.  Additionally, protein:DNA, protein:RNA, and RNA:DNA ratios 
were not affected by gender. 
As expected, steers demonstrated differences from heifers that are characteristic of 
greater lean growth such as lower plasma urea and greater serum IGF-I concentrations, in 
addition to numerically greater protein synthesis rates in the LM.   
Effects of Ractopamine and Interaction of Ractopamine with Gender  
Data for blood metabolites are presented in Tables 4.5 and 4.6.  Plasma glucose 
concentrations were not affected by ractopamine.  Ractopamine tended to decrease plasma urea 
concentrations (P = 0.06).  Growing Holstein steers demonstrated no change in plasma urea 
concentrations in response to ractopamine (Chapter 3 in this thesis).  In contrast, Dunshea and 
King (1994) reported a 5% decrease in plasma urea-N in gilts fed 20 ppm ractopamine for 22 d.  
Ractopamine increases lean tissue deposition and increases N retention (Chapter 3 of this thesis) 
and, therefore, would be expected to decrease urea production.  Serum insulin concentrations 
were not affected by ractopamine.  Similarly, growing Holstein steers demonstrated no change in 
insulin concentrations when fed ractopamine for 28 d (Chapter 3 of this thesis).  In response to 
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ractopamine feeding, serum IGF-I concentrations (Figure 4.1) were decreased in heifers on d 14, 
not different in steers on d 14 and in heifers on d 28, but increased in steers on d 28 (gender × 
ractopamine × day interaction; P = 0.03).  The serum IGF-I response in steers fed ractopamine 
might allow an extended growth curve enabling them to deposit more lean tissue compared to 
heifers.  Heifers fed ractopamine had lower DMI and it is plausible that the lower DMI, 
independent of ractopamine, resulted in decreases in circulating IGF-I concentrations.  
Ellenberger et al. (1989) demonstrated decreases in serum IGF-I concentrations when steers were 
feed restricted.  The majority of IGF-I in circulation is derived from hepatic production and, 
therefore, changes in serum IGF-I concentrations in steers and heifers fed ractopamine could be 
attributed to ractopamine affecting hepatic IGF-I synthesis or release, or ractopamine might alter 
the IGFBP such that IGF-I clearance from the blood is affected.  Beermann et al. (1987) reported 
46.5 and 21.5% decreases in serum IGF-I concentrations in lambs fed cimaterol for 6 and 12 wk 
compared to lambs not fed cimaterol.  Serum IGF-I concentrations tended to decrease by 13% in 
Holstein steers in response to feeding 200 mg/d ractopamine for 28 d (Chapter 3 in this thesis).   
In vitro skeletal muscle protein synthesis and degradation were measured as an evaluation 
of skeletal muscle protein metabolism.  Protein synthesis and degradation rates are presented in 
Tables 4.5 and 4.6.  Protein synthesis rates were not affected by ractopamine.  Ractopamine 
decreased in vitro protein degradation rates in LM (P = 0.03), but numerically increased them in 
BF (P = 0.19).  Wheeler and Koohmaraie (1992) demonstrated a 27% decrease in fractional 
protein degradation rates of skeletal muscle myofibrillar protein and a numerical increase in 
fraction protein synthesis rates of skeletal muscle myofibrillar protein after 3 wk in steers fed 3 
ppm of L644,969.  Bergen et al. (1989) reported that fraction protein synthesis and degradation 
rates were 4.4%/d and 3.4%/d for control and 6.1%/d and 4.9%/d in the semitendinosus of pigs 
fed 20 ppm ractopamine for 21 to 35 d.  Ractopamine decreased rates of protein degradation in 
the LM of steers and heifers in support of the data reported by Wheeler and Koohmaraie (1992), 
but this contrasts data reported by Bergen et al. (1989).  That protein degradation rates in the BF 
were numerically increased by ractopamine suggests a difference between muscles in response to 
ractopamine feeding.  Although rates of protein synthesis and degradation will not be reflective 
of in vivo rates due to the nature of the sample and assay, our goal was to assess changes due to 
ractopamine.  Our samples were collected using a Bergstrom biopsy needle that produced small 
tissue pieces, and this could limit our ability to measure true protein synthesis and degradation 
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rates.  Additionally, our in vitro protein synthesis and degradation assays did not differentiate the 
myofibrillar protein fraction from total protein and, therefore, differences may not reflect 
changes in myofibrillar protein turnover.    
Data for mRNA expression of IGF-I, IGFBP-3 and -5, MHC IIA, calpastatin, and β1-, β2-
, and β3-receptors in BF and LM are presented in Tables 4.5 and 4.6.  Ractopamine did not 
significantly alter mRNA expression of IGF-I in BF (P = 0.21) and in LM (P = 0.22), although in 
both muscles abundance of IGF-I mRNA was numerically increased.   In LM, mRNA expression 
of IGF-I decreased in growing Holstein steers fed 200 mg/d ractopamine for 14 or 28 d (Chapter 
3 in this thesis).   Sissom et al. (2007) demonstrated a reduction of IGF-I mRNA expression in 
response to ractopamine in semimembranosus of heifers initially implanted with 80 mg TBA/8 
mg E2 and re-implanted with 200 mg TBA 96 d prior to feeding 200 mg/d ractopamine for the 
final 28 d.  However, in the same study, heifers implanted with 200 mg TBA/20 mg E2 154 d 
prior to ractopamine feeding demonstrated a numerical increase in IGF-I mRNA expression in 
the semimembranosus, suggesting that the intensity of the implant program may affect the 
responsiveness of heifers to ractopamine.  Yimlamai et al. (2005) reported that clenbuterol fed to 
rats for 2 wk decreased protein expression of IGF-I in the plantaris muscle (fast twitch), but did 
not affect protein expression of IGF-I in the tibialis anterior muscle.  In contrast, Awede et al. 
(2002) demonstrated a 5-fold increase in IGF-I mRNA expression in the soleus muscle (slow 
twitch) of 3 mo old rats administered 10 ppm clenbuterol in the drinking water for 3 d.  Fiber 
composition of the muscle might determine responsiveness to β-agonists, but in our study, IGF-I 
mRNA expression numerically increased in both BF and LM due to the ractopamine.  Clearly, 
the role of local IGF-I expression in response to β-agonists is still equivocal.   
The IGFBP regulate activity and clearance of IGF-I.  The mRNA expression of IGFBP-3 
and -5 were not affected in LM or BF by ractopamine (P ≥ 0.42).   In contrast, Awede et al. 
(2002) demonstrated a 5-fold increase in IGFBP-5 mRNA expression in the soleus muscle of 3 
mo old rats administered clenbuterol for 3 d.  The biological activity of IGF-I is regulated by 1 of 
6 IGFBP.  A majority of IGF-I in circulation is bound to IGFBP, which can either inhibit or 
facilitate IGF-I binding to the IGF-I receptor (Duan, 2002).  The most abundant IGFBP in 
circulation is IGFBP-3, and IGFBP-3 and -5 have been implicated in inhibition of cell 
proliferation via IGF-I independent actions that negatively impact muscle growth (Kamango-
Sollo et al., 2005; Yang et al., 1999).  The lack of effect of ractopamine on mRNA expression of 
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IGFBP-3 and -5 in LM and BF suggest that, if ractopamine impacts IGFBP, it does so through 
effects on tissues other than muscle.  
Ractopamine decreased MHC IIA mRNA expression in BF (P = 0.04), but not in LM (P 
= 0.99).  Vestergaard et al. (1994) reported a decrease in frequency of type IIA fibers from 24.2 
to 8.6% in LM and from 24.3 to 6.7% in semitendinosus of Friesian bulls fed 0.06 ppm cimaterol 
for 90 d, whereas frequency of type IIB increased from 51.8 to 71.1% in LM and from 61.8 to 
81.6% in the semitendinosus.  Miller et al. (1988) demonstrated a 19% increase in type II fiber 
diameter with no change in type I diameter and frequency of type I and II in the LM of heifers 
fed 10 mg/d clenbuterol for 50 d.  Depreux et al. (2002) demonstrated a decrease in MHC IIA 
mRNA expression in LM and semimembranosus of pigs fed 20 ppm ractopamine for 28 d.  
These data demonstrate that administration of β-agonists can either convert slow twitch fibers to 
fast twitch fibers as demonstrated by changes in distribution and in gene expression of the MHC 
isoforms or alter protein turnover via changes in fiber diameter and in gene expression of the 
MHC isoforms.  Our MHC IIA data could suggest that ractopamine induced alterations in fiber 
type in BF, but not in LM.  It is also possible that decreases in MHC IIA mRNA expression in 
the BF in response to ractopamine could result from a conservation mechanism wherein less 
MHC IIA isoform is degraded, leading to decreases in need for myofibrillar protein synthesis; 
however, in vitro protein degradation rates in the BF were numerically increased and changes in 
calpastatin mRNA was not affected in BF.  Ractopamine did not affect calpastatin mRNA 
expression in either BF or LM, although it did numerically increase calpastatin mRNA 
expression in LM (P = 0.19).  Calpastatin regulates the activity of m-calpain and µ-calpain which 
are responsible for initiating myofibrillar protein disassembly and, therefore, changes in mRNA 
expression of calpastatin could reflect changes in protein degradation.  Parr et al. (1992) 
observed increases in activity of m-calpain and calpastatin by 27 and 76% in LM of steers fed 
1.5 ppm cimaterol for 16 wk.  In addition, mRNA levels of m-calpain and calpastatin were 
increased by 30 and 96% due to cimaterol treatment.  The authors were the first to report 
simultaneous up-regulation of m-calpain and calpastatin due to β-agonist feeding and suggest 
that this may be the physiological response observed when β-agonists are used.  Koohmaraie et 
al. (1991) demonstrated a 63% increase in calpastatin activity whereas activities of µ-calpain and 
m-calpain were not affected in the BF of lambs fed 4 ppm L644,969 for 6 wk.  We did not observe 
significant changes in expression of calpastatin mRNA, and the numeric response in LM 
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represented only a 19% increase.  Benson et al. (1991) observed a reduction in 3-methylhistidine 
concentration in the medium at 0 and 2 h of incubation of soleus muscle removed from fasted 
rats treated with 2 ppm clenbuterol in the water for 2 d compared to control fasted rats, 
demonstrating a reduction in degradation of myofibrillar protein.                   
β1- and β2-receptor mRNA expressions in the BF were not affected by treatment.  
Ractopamine tended to decrease β1-receptor mRNA abundance in LM in steers on d 14 and in 
heifers on d 28 (gender × ractopamine × day interaction; P = 0.11).  Ractopamine decreased β2-
receptor mRNA expression in LM of steers on d 14, but increased it in steers on d 28 (gender × 
ractopamine × day interaction; P = 0.03).  Sissom et al. (2007) reported that, in the 
semimembranosus of implanted heifers, ractopamine did not affect β1-receptor mRNA 
abundance and tended to increase β2-receptor mRNA expression.  Implanted yearling steers had 
increased β2-receptor mRNA expression in semimembranosus when fed ractopamine for 28 d 
(Winterholler et al., 2007).  Growing Holstein steers fed ractopamine for 28 d demonstrated 
decreases in β1- and β2-receptor mRNA expression in LM (Chapter 3 in this thesis).  In BF, 
ractopamine numerically decreased mRNA expression of β3-receptor in steers, whereas 
expression in heifers were not affected by treatment (gender × ractopamine, P = 0.19).  
Ractopamine did not affect β3-receptor mRNA expression in growing Holstein steers (Chapter 3 
of this thesis).  Chronic exposure to β-agonists is suggested to lead to desensitization of the β-
receptors (Hausdorff et al., 1990) resulting in lose of the β-receptors.  We observed only numeric 
decreases in mRNA for β-receptors, although these numeric decreases were present for all 3 
receptors in both muscles. 
Data for RNA, DNA, and protein concentrations and protein:DNA, protein:RNA, and 
RNA:DNA ratios are presented in Table 4.7.  No effect of ractopamine on RNA, DNA, and 
protein concentration was observed.  Additionally, protein:DNA, protein:RNA, and RNA:DNA 
ratios were not affected by ractopamine.  O’Connor et al. (1991) demonstrated 42 and 25% 
reductions in DNA concentrations, 25 and 12% increases in RNA concentrations, and 1 and 13% 
increases in protein concentrations in the ST of ram lambs fed 10 ppm cimaterol for 3 and 6 wk.  
Additionally, in that study, protein:DNA increased by 76 and 51%, protein:RNA decreased by 21 
and 2%, and RNA:DNA was increased by 109 and 52%.  Beermann et al. (1987) demonstrated a 
22% decrease in DNA concentration in semitendinosus in lambs fed 10 ppm of cimaterol for 7 
wk, and RNA concentrations in semitendinosus were increased by 9% and protein concentrations 
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were increased by 8.1% when lambs were fed cimaterol for 12 wk.  Protein:DNA was increased 
by 22 and 8%, protein:RNA was decreased by 5 and 1%, and RNA:DNA was increased by 29 
and 10% after 7 and 12 wk of cimaterol feeding.  In our study, differences among treatments 
were not observed, which may reflect no true difference or an inability to detect modest 
differences that might have been present. 
Conclusions    
Our results suggest that ractopamine fed to steers and heifers implanted with TBA/E2 
impacts in vitro protein degradation rates differently between the LM and BF.  Feeding 
ractopamine seems to change the muscle fiber composition in BF as shown by decreases in MHC 
IIA expression.  The role of IGF-I, if any, in mediating the action of ractopamine warrants 
further research.  Although there were a few criteria for which ractopamine led to differences in 
response between steers and heifers, there were no striking disparities to suggest that the 
effectiveness of ractopamine would markedly differ between genders. 
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Table 4.1 Composition of the diet fed to finishing steers and heifers 
 
Item % of DM 
Steam-flaked corn 77.5 
Alfalfa hay 10.0 
Steep liquor 6.0 
Solvent soybean meal 4.0 
Limestone 1.56 
Urea 0.50 
Salt 0.30 
Vitamin/mineral/drug premix 
1
 0.14 
1
 To provide per kilogram of diet DM:  60 mg of Mn, 60 mg of Zn, 10 mg of Cu, 0.6 
mg of I, 0.25 mg of Se, 0.1 mg of Co, 2,650 IU of vitamin A, 30 mg of monensin 
(Rumensin 80, Elanco Animal Health, Greenfield, IN), and 9 mg of tylosin (Tylan 40, 
Elanco Animal Health). 
  
 
9
9
 
Table 4.2  Sequence of bovine specific PCR primers and TaqMan Probes to be used for determination of expression of mRNA of 
IGF-I, IGFBP-3 and -5, β1-, β2-, and β3-adrenergic receptors, calpastatin, and myosin heavy chain IIA 
 Primer and Probes Sequence (5’ to 3’) 
IGF-I (Accession # X15726)  
   Forward TGTGATTTCTTGAAGCAGGTGAA 
   Reverse AGCACAGGGCCAGATAGAAGAG 
   TaqMan probe 6FAM-GCCCATCACATCCTCCTCGCA-TAMRA 
IGFBP-3 (Accession # M76478)  
   Forward CATTCCCAACTGCGACAAGA 
   Reverse GCAGAAACCCCGCTTCCT 
   TaqMan probe 6FAM-AGAAAAAGCAGTGCCGCCCTTCCAA-TAMRA 
IGFBP-5 (Accession # M62782)  
   Forward TCTTCCGGCCCAAACACA 
   Reverse TCTTTCTGCGGTCCTTCTTCAC 
   TaqMan probe 6FAM-CGCATCTCCGAGCTGAAGGCTGAA-TAMRA 
β1-adrenergic receptor (Accession # AF188187)  
   Forward GTGGGACCGCTGGGAGTAT 
   Reverse TGACACACAGGGTCTCAATGC 
   TaqMan probe 6FAM-CTCCTTCTTCTGCGAGCTCTGGACCTC-TAMRA 
β2-adrenergic receptor (Accession # NM_174231)  
   Forward CAGCTCCAGAAGATCGACAAATC 
   Reverse CTGCTCCACTTGACTGACGTTT 
   TaqMan probe 6FAM-AGGGCCGCTTCCATGCCC-TAMRA 
β3-adrenergic receptor (Accession # X85961)  
   Forward AGGCAACCTGCTGGTAATCG 
   Reverse GTCACGAACACGTTGGTCATG 
   TaqMan probe 6FAM-CCCGGACGCCGAGACTCCAG-TAMRA 
Calpastatin (Accession # X67333)  
   Forward CCCTGGATCAACTTTCTGACAGT 
   Reverse TGACTTTATCCTCTACAGGTTTATTCTCA 
   TaqMan probe 6FAM-TCGGGCAAAGACAGCCTGATCCA-TAMRA 
Myosin heavy chain IIA (Accession # AB059398)  
   Forward CCCCGCCCCACATCTT 
   Reverse TCTCCGGTGATCAGGATTGAC 
   TaqMan probe 6FAM-TCTCTGACAACGCCTATCAGTTCAT-TAMRA 
 
  
1
0
0
 
 
Table 4.3 Effect of ractopamine on growth characteristics of finishing steers and heifers 
 No ractopamine  Ractopamine, 200 mg/d  P-value1 
Item Heifers Steers  Heifers Steers SEM G R G × R 
Initial BW, kg 476 509  471 516 6.9 <0.001 0.93 0.22 
Final BW, kg 516 548  503 561 10.2 <0.001 0.99 0.07 
DMI, kg/d 8.42
y
 8.58
 y
  7.07
 x
 8.33
 y
 0.37 0.01 0.007 0.05 
ADG, kg 1.42 1.41  1.17 1.64 0.18 0.17 0.94 0.15 
G:F 0.169 0.159  0.164 0.193 0.019 0.59 0.42 0.28 
G:F above maintenance
2
 0.302 0.287  0.337 0.372 0.033 0.76 0.07 0.44 
1
 G = gender, R = ractopamine. 
2
 Calculated with feed (2.14 Mcal NEm/kg) necessary to meet NEm requirements subtracted from DMI; NEm requirements = 0.077 
Mcal × (BW × 0.96)
0.75
. 
x,y 
Means in rows not bearing a common superscript differ, P < 0.05.
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Table 4.4 The effect of gender on blood metabolites, protein turnover, and gene expression  
Item Heifers Steers SEM P-value 
Serum --- ng/mL ---   
  IGF-I 488 695 29 <0.001 
  Insulin 1.02 1.32 0.21 0.32 
Plasma --- mmol/L ---   
  Urea-N 5.26 4.59 0.16 0.003 
  Glucose 5.5 6.5 0.39 0.08 
Protein turnover     
  Protein synthesis --- µg Tyr/(g wet tissue × h) ---   
     Biceps femoris 0.313 0.309 0.011 0.76 
     LM 0.291 0.304 0.0093 0.10 
  Protein degradation --- µg Tyr/(g protein × h) ---   
     Biceps femoris 92 86 5.9 0.42 
     LM 68 66 3.9 0.64 
Gene expression     
  Biceps femoris --- Arbitrary units, 10
-6
 ---   
     IGF-I 4.0 5.3 0.44 0.05 
     IGFBP-3 172 193 22 0.32 
     IGFBP-5 702 846 89 0.26 
     Calpastatin 201 209 16 0.59 
     Myosin heavy chain IIA 1355 1455 149 0.56 
     β1-adrenergic receptor 0.71 0.98 0.21 0.37 
     β2-adrenergic receptor 113 128 16 0.38 
     β3-adrenergic receptor 3.4 5.5 0.94 0.08 
  LM     
     IGF-I 4.2 3.8 0.40 0.33 
     IGFBP-3 169 217 25 0.10 
     IGFBP-5 640 801 83 0.17 
     Calpastatin 179 207 16 0.22 
     Myosin heavy chain IIA 1694 1594 128 0.59 
     β1-adrenergic receptor 0.56 0.54 0.15 0.92 
     β2-adrenergic receptor 86 108 15 0.11 
     β3-adrenergic receptor 3.1 3.4 1.0 0.79 
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Table 4.5 The effect of ractopamine and gender on blood metabolites, protein turnover, and gene expression in finishing steers and heifers 
1
 R = ractopamine, D = day, G = gender. 
x,y,z 
Means in rows not bearing a common superscript differ, P < 0.05.
 Day 14  Day 28   
 No ractopamine  200 mg/d ractopamine  No ractopamine  200 mg/d ractopamine  P-values1 
Item Heifers Steers  Heifers Steers  Heifers Steers  Heifers Steers SEM R R × D G × D G × R G × R × D 
Serum --- ng/mL ---       
   IGF-I 669
z
 691
z
  607
y
 618
y,z
  578
x,y
 534
x
  505
x
 680
z
 44 0.51 0.04 0.33 0.04 0.03 
   Insulin 1.39 1.39  1.10 1.50  1.03 1.16  1.20 1.17 0.32 0.99 0.39 0.49 0.80 0.20 
Plasma --- mmol/L ---       
   Urea-N 4.45 4.60  4.02 4.18  5.81 5.28  5.27 5.26 0.26 0.06 0.55 0.08 0.47 0.30 
   Glucose 5.0 6.6  5.1 5.5  5.3 7.6  5.6 6.0 1.0 0.34 0.93 0.77 0.20 0.75 
Protein turnover        
   Protein synthesis --- µg Tyr/(g wet tissue × h) ---       
      Biceps femoris 0.319 0.333  0.329 0.323  0.276 0.270  0.291 0.287 0.017 0.53 0.41 0.64 0.71 0.56 
      LM 0.312 0.318  0.304 0.328  0.257 0.286  0.263 0.259 0.014 0.58 0.38 0.88 0.69 0.07 
   Protein degradation --- µg Tyr/(g protein × h) ---       
       Biceps femoris 87 81  110 85  92 74  107 79 12 0.19 0.75 0.56 0.42 0.66 
      LM 66 74  62 59  73 68  56 64 7 0.03 0.85 0.88 0.96 0.13 
Gene expression --- Arbitrary units, 10
-6
 ---       
    Biceps femoris                  
      IGF-I 3.1 5.5  5.3 5.7  3.0 4.2  4.3 4.8 1.0 0.21 0.76 0.55 0.40 0.52 
      IGFBP-3 116 172  135 145  214 243  192 188 46 0.42 0.44 0.65 0.43 0.90 
      IGFBP-5 530 877  728 565  742 796  658 771 142 0.61 0.99 0.96 0.29 0.90 
      Calpastatin 107 183  141 164  237 205  240 214 38 0.73 0.97 0.13 0.54 0.57 
      Myosin heavy chain IIA 1314 1489  948 837  1279 1336  906 1347 254 0.04 0.31 0.50 0.88 0.30 
      β1-adrenergic receptor 0.24 1.85  0.18 0.57  0.52 0.47  0.64 0.31 0.7 0.38 0.39 0.12 0.33 0.54 
      β2-adrenergic receptor 69 15  62 114  118 117  123 112 35 0.62 0.58 0.10 0.64 0.78 
      β3-adrenergic receptor 1.4 8.4  1.2 3.3  2.3 5.8  2.5 2.4 2.9 0.22 0.77 0.46 0.19 0.86 
   LM                  
      IGF-I 3.7 3.6  6.1 3.8  2.9 4.2  3.9 3.5 1.0 0.22 0.31 0.16 0.11 0.83 
      IGFBP-3 100 267  193 258  214 221  191 197 58 0.80 0.29 0.08 0.48 0.42 
      IGFBP-5 440 1145  703 807  594 755  531 716 222 0.75 0.96 0.36 0.30 0.22 
      Calpastatin 115 228  191 213  195 192  223 256 43 0.19 0.78 0.33 0.63 0.24 
      Myosin heavy chain IIA 1010 1434  1262 1105  1624 1961  1978 1687 353 0.99 0.81 0.73 0.18 0.94 
      β1-adrenergic receptor 0.22 0.92  0.32 0.13  0.80 0.53  0.46 0.60 0.4 0.35 0.59 0.42 0.64 0.11 
      β2-adrenergic receptor 58
x
 194
y
  68
x
 65
x
  103
x
 106
x
  104
x
138
x
 30 0.28 0.05 0.23 0.17 0.03 
      β3-adrenergic receptor 2.1  7.3  2.5 1.1  3.5    4.7  3.1 2.9 2.1 0.26 0.26 0.36          0.25 0.10 
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Table 4.6 The effect of ractopamine on blood metabolites, protein turnover, and gene expression 
Item 
No 
ractopamine 200 mg/d ractopamine SEM P-value 
Serum --- ng/mL ---   
   IGF-I 618 602 20 0.51 
   Insulin 1.24 1.24 0.22 0.99 
Plasma --- mmol/L ---   
   Urea-N 5.03 4.65 0.15 0.06 
   Glucose 6.1 5.5 0.44 0.34 
Protein turnover     
   Protein synthesis --- µg Tyr/(g wet tissue × h) ---   
      Biceps femoris 0.300 0.307 0.011 0.53 
      LM 0.293 0.288 0.011 0.58 
   Protein degradation --- µg Tyr/(g protein × h) ---   
      Biceps femoris 84 95 7.1 0.19 
      LM 70 60 4.1 0.03 
Gene expression     
    Biceps femoris --- Arbitrary units, 10
-6
 ---   
      IGF-I 3.93 5.02 0.59 0.21 
      IGFBP-3 186 165 30 0.42 
      IGFBP-5 736 680 80 0.61 
      Calpastatin 183 190 19 0.73 
      Myosin heavy chain IIA 1354 1009 152 0.04 
      β1-adrenergic receptor 0.77 0.43 0.28 0.38 
      β2-adrenergic receptor 115 103 17 0.62 
      β3-adrenergic receptor 4.5 2.3 1.2 0.22 
   LM     
      IGF-I 3.60 4.32 0.41 0.22 
      IGFBP-3 200 210 27 0.80 
      IGFBP-5 734 689 103 0.75 
      Calpastatin 183 221 20 0.19 
      Myosin heavy chain IIA 1507 1508 159 0.99 
      β1-adrenergic receptor 0.62 0.38 0.22 0.35 
      β2-adrenergic receptor 115 94 15 0.28 
      β3-adrenergic receptor 4.4 2.4 1.5 0.26 
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Table 4.7 Effects of ractopamine and gender on RNA, DNA, and protein concentrations and protein:DNA, protein:RNA, and 
RNA:DNA ratios in the biceps femoris and LM on day 28   
 No Ractopamine 
 200 mg/d 
ractopamine           P-value
1 
Item Heifers Steers  Heifers Steers SEM G R G × R 
Biceps femoris          
   RNA concentration, mg/g 0.199 0.206  0.200 0.209 0.014 0.62 0.90 0.94 
   DNA concentration, mg/g 0.220 0.207  0.181 0.210 0.023 0.71 0.40 0.32 
   Protein concentration, mg/g 103 102  103 101 4.2 0.65 0.91 0.85 
   Protein:DNA 512 563  573 556 72 0.80 0.69 0.62 
   Protein:RNA 535 531  529 513 46 0.82 0.77 0.88 
   RNA:DNA 1.02 1.15  1.10 1.12 0.16 0.60 0.86 0.67 
LM          
   RNA concentration, mg/g 0.193 0.193  0.186 0.203 0.013 0.42 0.84 0.41 
   DNA concentration, mg/g 0.161 0.171  0.161 0.166 0.025 0.74 0.90 0.92 
   Protein concentration, mg/g 100 107  97 101 3.2 0.11 0.11 0.62 
   Protein:DNA 686 860  698 634 128 0.65 0.38 0.33 
   Protein:RNA 529 598  525 508 50 0.55 0.29 0.33 
   RNA:DNA 1.33 1.44  1.37 1.30 0.23 0.91 0.72 0.60 
1
 G = gender, R = ractopamine. 
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Figure 4.1 Serum IGF-I concentrations in heifers and steers fed diets with 0 or 200 mg/d 
ractopamine.  
The use of d 0 data in covariate analysis removed much of the gender effects.  Gender × 
Ractopamine × Day interaction, P = 0.03.  
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